[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 593
1. Kanazawa A, Shiozawa M, Inagaki D, Morinaga S, Sugimasa Y, Oshima T, Rino Y, Masuda M, Imada T, Akaike M: Risk factors for intrahepatic recurrence after curative surgical treatment of colorectal liver metastases. Hepatogastroenterology; 2010 Sep-Oct;57(102-103):1183-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for intrahepatic recurrence after curative surgical treatment of colorectal liver metastases.
  • BACKGROUND/AIM: Hepatic resection has been regarded as the only curative treatment for colorectal liver metastases.
  • Lymph node metastases of primary colorectal cancer and synchronous liver metastases were found to be independently associated with intrahepatic recurrence.
  • CONCLUSION: We suggest that neoadjuvant chemotherapy before hepatectomy should be considered as feasible treatment for reducing intrahepatic recurrence in two cases; One case is resectable synchronous liver metastases from colorectal cancer, and the other is resectable metachronous liver metastases with primary regional lymph node metastases from colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Neoplasm Recurrence, Local / etiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21410055.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


2. Ng WW, Cheung YS, Wong J, Lee KF, Lai PB: A preliminary analysis of combined liver resection with new chemotherapy for synchronous and metachronous colorectal liver metastasis. Asian J Surg; 2009 Oct;32(4):189-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preliminary analysis of combined liver resection with new chemotherapy for synchronous and metachronous colorectal liver metastasis.
  • OBJECTIVE: To compare the survival between patients with synchronous and metachronous colorectal liver metastases after hepatectomy with new generation of peri-operative chemotherapy.
  • METHODS: From October 2002 to January 2008, patients receiving hepatectomy for synchronous or metachronous colorectal liver metastasis were studied retrospectively.
  • RESULTS: Fifty-five patients (synchronous group=35, metachronous group=20) underwent hepatectomy for colorectal liver metastases.
  • They had received less hepatic curative hepatectomy (81.1% vs. 100%) with a higher rate of peri-operative chemotherapy (91.4% vs. 50%) and postoperative morbidity (25.7% vs. 0%).
  • However both groups had no statistical significant difference in median overall survival (OS) and disease free survival (DFS).
  • Inferior OS and DFS were observed in the synchronous group for patients who had no peri-operative chemotherapy or those showing poor response to chemotherapy.
  • CONCLUSION: Synchronous colorectal liver metastasis is not a poor prognostic factor for survival when compared with the metachronous metastasis.
  • Globally curative hepatectomy in combination of new generation of chemotherapy is recommended for the management of resectable colorectal liver metastasis.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19892621.001).
  • [ISSN] 0219-3108
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, Palmerini E, Briccoli A, Pignotti E, Balladelli A, Picci P: Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol; 2006 Dec;28(12):774-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
  • We evaluated the rate of second malignancies in 1205 patients with osteosarcoma of the extremity treated at our Institution with different protocols of adjuvant and neoadjuvant chemotherapy.
  • Twenty-six patients (2.15%) developed a second malignant neoplasm at a median of 7.6 years (1 to 25 y) after primary osteosarcoma treatment.
  • Of these, 2 developed a third cancer which were not considered in the series.
  • Second neoplasms were leukemia (10), breast (7), lung (2), kidney (2), central nervous system cancer (2), soft tissue (1), parotid (1), and colon (1).
  • The rate of second neoplasms was significantly higher in female patients, and the latent period shorter in hematologic tumors compared with solid tumors.
  • Ten of these 26 patients are disease free at a median of 7.7 years (range 1 to 15 y) after the last treatment.
  • The rate of second malignancies observed in the osteosarcoma group was significantly higher than that observed in the control group of 1160 patients with benign tumors treated in the same period at our Institute (2.2% vs. 0.8%, P<0.009).
  • Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented.
  • [MeSH-major] Neoplasms, Second Primary / epidemiology. Osteosarcoma
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Incidence. Infant. Male. Neoplasms / drug therapy. Neoplasms / epidemiology. Retrospective Studies. Risk Factors. Sex Factors. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164644.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Belluco C, Mammano E, Petricoin E, Prevedello L, Calvert V, Liotta L, Nitti D, Lise M: Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin Chim Acta; 2005 Jul 24;357(2):180-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In cases with unresectable liver disease, more effective agents are needed, since chemotherapy achieves median survival of only 15 months.
  • Protein kinases coordinate complex functions that are often disregulated in cancer and are therefore considered important targets for molecular therapeutics.
  • In this study, we investigated the phosphoproteomic status of different protein kinases in primary CRC and in liver metastases.
  • METHODS: The status of 29 key endpoints was evaluated using reverse phase protein array on laser capture microdissected neoplastic cells from five primary CRCs without metastases, three patient-matched primary CRCs and synchronous liver metastases and five CRC metachronous liver metastases.
  • RESULTS: Unsupervised hierarchical two-way clustering analysis showed an entirely different phosphoproteomic profile in primary CRCs compared to liver metastases.
  • This difference was observed also in primary and metastatic patient-matched lesions.
  • CONCLUSIONS: Our findings of different signaling pathways between primary and metastatic CRC suggest a possible microenvironment effect, and emphasize the need to perform molecular network analysis of metastatic tissue when molecular targeting is considered.
  • [MeSH-major] Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Phosphotransferases / metabolism. Protein Array Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921671.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.- / Phosphotransferases
  •  go-up   go-down


5. El-Gaidi MA, Eissa EM: Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center. Pediatr Neurosurg; 2010;46(4):272-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center.
  • OBJECTIVE: To investigate the demographic, clinical, radiological, pathological and surgical features and outcomes of infantile intracranial neoplasms, the second most common neoplasm in infants.
  • RESULTS: Out of 451 patients with primary intracranial neoplasms (age 0-14 years), 21 infants (<1 year) underwent surgery, representing 4.7% of total cases.
  • The most common tumor was choroid plexus papilloma (23.8%), followed by teratoma (19%) then astrocytoma and ependymoma (14.3% each).
  • Three patients received chemotherapy, but none received radiotherapy.
  • The statistically significant predictors of prognosis were the extent of resection and tumor grade.
  • CONCLUSION: Although the prognosis for infantile intracranial neoplasms is worse than for older children, an overall promising outcome with low operative morbidity and mortality was achieved using gross total excision and appropriate adjuvant chemotherapy as part of a multidisciplinary approach.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Papilloma, Choroid Plexus / mortality. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Egypt / epidemiology. Ependymoma / drug therapy. Ependymoma / mortality. Ependymoma / surgery. Female. Humans. Infant. Infant, Newborn. Male. Medulloblastoma / drug therapy. Medulloblastoma / mortality. Medulloblastoma / surgery. Morbidity. Neurilemmoma / drug therapy. Neurilemmoma / mortality. Neurilemmoma / surgery. Prognosis. Quality of Life. Referral and Consultation / statistics & numerical data. Retrospective Studies. Teratoma / drug therapy. Teratoma / mortality. Teratoma / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21160236.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Martinet S, Ozsahin M, Belkacémi Y, Landmann C, Poortmans P, Oehlere C, Scandolaro L, Krengli M, Maingon P, Miralbell R, Studer G, Chauvet B, Marnitz S, Zouhair A, Mirimanoff RO: Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys; 2003 Mar 15;55(4):892-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Between 1980 and 1999, 90 consecutive patients with primary orbital lymphoma were treated in 13 member institutions of the Rare Cancer Network.
  • All patients underwent RT with a median dose of 34.2 Gy (range 4.0-50.4).
  • Eleven patients received chemotherapy in addition to RT.
  • The rate of systemic relapse was 20%, and 9% of the patients developed metachronous contralateral eye involvement.
  • The 5-year disease-free survival, overall survival, and cause-specific survival rate was 65%, 78%, and 87%, respectively.
  • In univariate analyses, the statistically significant favorable prognostic factors were younger age, low grade, normal erythrocyte sedimentation rate, absence of muscular infiltration, complete response to treatment, conjunctival localization, and normal lactate dehydrogenase value for overall survival, disease-free survival, and freedom from treatment failure.
  • In multivariate analysis, the favorable factors were younger age and low grade for overall and disease-free survival; a favorable response, conjunctival localization, and complete staging were highly significant for disease-free survival and freedom from treatment failure.
  • CONCLUSION: Moderate- to low-dose RT alone is able to control primary orbital lymphoma with low morbidity.
  • Prognostic factors were identified that could be useful in the overall management of this uncommon site of primary lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Orbital Neoplasms / radiotherapy
  • [MeSH-minor] Age Factors. Aged. Analysis of Variance. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Recurrence. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12605966.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


7. Hashimoto K, Suzuki M: [A case of metachronous liver metastasis from gastric cancer treated with multidisciplinary therapy including hepatectomy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2324-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metachronous liver metastasis from gastric cancer treated with multidisciplinary therapy including hepatectomy].
  • A 73-year-old man underwent a distal gastrectomy with dissection of D2 lymph nodes for type 2 gastric cancer at the front wall of pyloric antrum in June 2006 (Pathological finding was moderately differentiated adenocarcinoma, T2, N0, H0, P0, M0, fStage IB).
  • Although he was given UFT and PSK for postoperative adjuvant therapy, MRI showed a liver metastasis at segment 6 of the liver in June 2007.
  • After hepatectomy, 5 courses of S-1 as adjuvant therapy were administered.
  • However, another metachronous liver metastasis appeared at segment 8 in August 2008.
  • After 3 courses of S-1 and CDDP, we performed radiofrequency ablation (RFA) therapy and a good cauterization effect was obtained.
  • We experienced a case of metachronous liver metastasis from gastric cancer treated with multidisciplinary therapy that was beneficial for a long term survival.
  • [MeSH-major] Adenocarcinoma / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Neoplasms, Second Primary / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Catheter Ablation. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Humans. Male. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037410.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. McGovern SL, Williams MD, Weber RS, Sabichi A, Chambers MS, Martin JW, Chao KS: Three synchronous HPV-associated squamous cell carcinomas of Waldeyer's ring: case report and comparison with Slaughter's model of field cancerization. Head Neck; 2010 Aug;32(8):1118-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with squamous cell carcinoma (SCC) of the oropharynx have an 8% to 20% risk of a synchronous or metachronous second malignancy.
  • METHODS: We report the case of a 46-year-old man with 3 simultaneous primary malignancies of Waldeyer's ring: HPV-positive SCC of both tonsils and the nasopharynx, with bilateral neck metastases.
  • RESULTS: The patient received induction chemotherapy followed by definitive radiotherapy and remains free of disease at 18 months.
  • CONCLUSION: Comparison with the Slaughter model of field cancerization suggests that HPV-positive SCC of the head and neck may have a distinct mechanism for the development of multifocal disease.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Neoplasms, Multiple Primary / virology. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / virology. Papillomavirus Infections / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley Periodicals, Inc. Head Neck, 2009.
  • (PMID = 19572386.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Holsinger FC, Lin HY, Bassot V, Laccourreye O: Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx. Cancer; 2009 Sep 1;115(17):3909-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx.
  • BACKGROUND: The current study was conducted to determine the long-term outcomes of patients with squamous cell carcinoma of the larynx and pharynx who were treated with platin-based exclusive chemotherapy (EC) after they achieved a complete clinical response (CCR) to induction chemotherapy.
  • METHODS: One hundred forty-two who achieved a CCR after platin-based induction chemotherapy were treated exclusively with additional chemotherapy, and 98.6% were followed for a minimum of 3 years or until death.
  • The main causes of death were metachronous second primary tumors (n = 27) and intercurrent disease (n = 21).
  • In multivariate analysis, primary tumor arising outside the glottic larynx (P = .0001) and a Charlson comorbidity index >1 (P = .0001) were associated with a statistically significant reduction in survival.
  • Salvage treatment resulted in an observed final local control rate of 93% that varied from 97.2% in patients who had glottic cancer to 88.7% in patients who had tumor originating from other sites (P = .097).
  • Combined chemotherapy with cisplatin and 5-fluorouracil (PF) allowed for the successful modulation of local therapy in 54.9% of patients.
  • CONCLUSIONS: For selected patients, EC may provide long-term, durable disease control.
  • For patients who developed recurrent disease after EC, this approach did not diminish survival and maintained function in the majority of patients.
  • Future work should be directed toward select markers of response to PF chemotherapy with which to identify those patients who are suited optimally for this approach.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Apr 15;51(8):1353-5 [6681726.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):327-33 [12525526.001]
  • [Cites] Head Neck Surg. 1983 Jul-Aug;5(6):500-7 [6885503.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1178-83 [3304610.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):83-91 [7819055.001]
  • [Cites] Head Neck. 1995 Sep-Oct;17(5):377-81 [8522437.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):838-47 [8622032.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2331-6 [8708725.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):565-74 [16814208.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] J Laryngol Otol. 2007 Feb;121(2):143-8 [17005065.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Laryngoscope. 2000 Jan;110(1):58-64 [10646717.001]
  • [Cites] Head Neck. 2004 Apr;26(4):365-72 [15054740.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1594-8 [11189100.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1504-11 [11745228.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • (PMID = 19551883.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA88084; United States / NCI NIH HHS / CA / K12 CA088084-09; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA097007; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / K12 CA088084; United States / NCI NIH HHS / CA / P50 CA97007
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS124415; NLM/ PMC3851301
  •  go-up   go-down


10. Preti M, Micheletti L, Ghiringhello B, Privitera S, Condello V, Chieppa P, Massobrio M: [Vulvar Paget's disease. Clinico-pathologic review of the literature]. Minerva Ginecol; 2000 May;52(5):203-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vulvar Paget's disease. Clinico-pathologic review of the literature].
  • In 1986 the International Society For the Study of Vulvar Disease classified vulvar Paget's disease (VPD) as a non-squamous intraepithelial lesion of the vulva.
  • Patients with VPD are at risk for a second synchronous or metachronous neoplasia: colo-rectal adenocarcinoma (more frequent in perianal localization of VPD), cervical adenocarcinoma, carcinoma of the transitional epithelium from the renal pelvis to urethra and mammary carcinoma.
  • Therapy for intraepithelial VPD is wide and deep surgical resection comprising all the skin appendages.
  • The role of chemotherapy and radiotherapy in the multimodal approach to extensive or recurring VPD is still controversial.
  • [MeSH-major] Paget Disease, Extramammary / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Neoplasm Recurrence, Local. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11048477.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] ITALY
  • [Number-of-references] 69
  •  go-up   go-down


11. Lee SH, Yoo KH, Sung KW, Kim JY, Cho EJ, Koo HH, Chung SE, Kang SW, Oh SY, Ham DI, Kim YD: Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma. Bone Marrow Transplant; 2008 Sep;42(6):385-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma.
  • Although external-beam radiation therapy (EBRT) has been an effective treatment modality in patients with bilateral advanced retinoblastoma, it significantly increases the risk of second malignancies and facial deformities.
  • This study aimed to evaluate the efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) for treatment, instead of EBRT, in children with bilateral advanced retinoblastoma.
  • Fourteen patients with bilateral retinoblastoma received chemotherapy, and local therapy was provided whenever possible.
  • When at least one functional eye could not be saved by chemoreduction and local therapy, tandem HDCT/ASCR was provided to avoid EBRT.
  • No second malignancy has developed to date.
  • HDCT/ASCR might be an effective treatment for bilateral advanced retinoblastoma, especially in cases in which at least one functional eye could not be preserved with chemoreduction and local therapy alone, and where EBRT was unavoidable.
  • Long-term follow-up and further studies are needed to evaluate the efficacy and toxicity of HDCT/ASCR as an alternative treatment to EBRT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Peripheral Blood Stem Cell Transplantation. Retinoblastoma / therapy

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574441.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Haimi M, Arush MW, Bar-Sela G, Gez E, Bernstein Z, Postovsky S, Barak AB, Kuten A: Nasopharyngeal carcinoma in the pediatric age group: the northern Israel (Rambam) medical center experience, 1989-2004. J Pediatr Hematol Oncol; 2005 Oct;27(10):510-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasopharyngeal carcinoma (NPC) is rare in children, accounting for less than 1% of all malignancies.
  • Radiation therapy has been the mainstay of treatment of many years, but to improve survival, the use of chemotherapy has been advocated.
  • Of the 13 patients, one patient had stage I, 6 had stage III, 5 had stage IV-A, and 1 had stage IV-B disease.
  • Ten patients (77%) had undifferentiated carcinoma (WHO type III) and three patients (23%) had nonkeratinizing carcinoma (WHO type II).
  • Most of the children received two or three courses of neoadjuvant multiagent chemotherapy consisting of cisplatin and 5-FU, followed by radiotherapy with doses in excess of 60 Gy.
  • Ten of the 13 patients (77%) are alive without disease 6 years after diagnosis (range 1-15 years).
  • One patient developed local and distant metastases 1 year after diagnosis and is currently receiving combined radiochemotherapy.
  • Nine patients (69%) developed moderate to severe long-term complications.
  • Pediatric NPC is curable by combined radiation and chemotherapy, with doses of radiation in excess of 60 Gy.
  • Long-term follow-up is important for early detection of second malignancies as well as for radiation-induced endocrinologic deficiencies and other normal tissue complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adolescent. Age Distribution. Carcinoma / epidemiology. Carcinoma / therapy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infant. Israel / epidemiology. Male. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217252.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE, COALL study group: Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia; 2010 Feb;24(2):298-308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A refinement of risk assessment has been achieved by in vitro drug sensitivity testing in COALL 92 and 97.
  • In patients with very sensitive leukaemic cells, therapy could be reduced without loss of efficacy.
  • In COALL 97, a further improvement in risk stratification was gained by the molecular assessment of minimal residual disease (MRD) under treatment, which proved to have a superior prognostic effect when compared with in vitro drug sensitivity testing.
  • Importantly, the gradual reduction in central nervous system (CNS) irradiation led to a decreased incidence of brain tumours as a second malignancy.
  • In general, the prevention of treatment-related late effects will be one of the major issues in future studies.
  • It remains to be shown whether prolonged infusions of anthracyclines, which have been implemented into the COALL studies after equal efficacy compared with short-time infusions was confirmed, will be associated with fewer cardiac late effects.
  • Another way to prevent late effects may be a more refined risk assessment allowing for a reduction in cumulative treatment burden.
  • A great challenge in the future will be to improve the overall treatment results, which very likely can only be achieved by the identification of molecularly defined subgroups to which novel, rational therapeutic strategies can be applied.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Neoplasm Recurrence, Local / therapy. Neoplasm, Residual / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunophenotyping. Infant. Leukocyte Count. Male. Prognosis. Remission Induction. Risk Factors. Survival Rate. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20016530.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Pongratz; Otte J; Jorch N; Spaar HJ; Lieber T; Siegert; Göbel U; Janssen G; Beck JF; Weigel S; Streitberger; Nürnberger W; von Klinggräff C; Westerbeck K; Thomas P; Völpel S; Weissbach G; Bierbach U; Gutjahr P; Althaus I; Roos R; Klose P; Graubner U; Schmidt I; Haas; Drescher; Müller H; Kolb R; Wolff J; Peters O; Weber J; Dohrn
  •  go-up   go-down


14. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ, Nevill TJ: High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood; 2005 Aug 15;106(4):1473-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.
  • Beginning in 1985, patients in British Columbia with Hodgkin lymphoma (HL) that was not controlled by conventional chemotherapy routinely underwent high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT).
  • Data were obtained retrospectively on the first 100 patients that underwent HD-ASCT for HL in Vancouver, focusing on relapse, treatment-related complications, and the occurrence of late events.
  • OAS was significantly better in patients in first relapse (67%) than in patients with primary refractory-induction failure (39%) and advanced disease (29%) (P = .002).
  • Treatment-related mortality, including death from second malignancy, was 17% at 15 years.
  • Cumulative risk of a second malignancy was 9% at 15 years.
  • Karnofsky performance status was at least 90% in 47 patients although hypogonadism (20 patients), hypothyroidism (12 patients), unusual infections (10 patients), anxiety or depression (7 patients), and cardiac disease (5 patients) were not uncommon in survivors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Canada. Cause of Death. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / mortality. Probability. Retrospective Studies. Salvage Therapy. Survival Rate. Transplantation, Autologous. Treatment Outcome


15. Pramateftakis MG: Optimizing colonic cancer surgery: high ligation and complete mesocolic excision during right hemicolectomy. Tech Coloproctol; 2010 Nov;14 Suppl 1:S49-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was located in the cecum in 37% of patients, the ascending colon in 58% of the patients and the hepatic flexure in 5% of the patients.
  • Out of all patients, 48 (42%) received adjuvant chemotherapy.
  • One patient developed a metachronous rectal carcinoma 28 months after his surgery, for which he underwent an abdoperineal resection.
  • Twenty patients (26.3%) died due to metastatic disease before completing 5 years of follow-up.
  • It is important to remember that colon cancer treatment today is multimodal and that the improvement in patients' survival in the last decades is surely linked with the improvement in chemotherapy and the advances in the agents used.
  • However, optimal surgery is with no doubt an important element of good oncological outcome, as the experience with rectal cancer treatment has taught us.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colon / blood supply. Colon / surgery. Colonic Neoplasms / surgery. Female. Humans. Ligation. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2009;48(8):1152-6 [19863223.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):349-54 [17693281.001]
  • [Cites] Colorectal Dis. 2009 May;11(4):354-64; discussion 364-5 [19016817.001]
  • [Cites] J R Soc Med. 1988 Sep;81(9):503-8 [3184105.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):602-10 [16998369.001]
  • (PMID = 20697925.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Huang JF, He J: [Clinical characteristics and prognostic factors in metachronous primary esophageal and gastric carcinomas]. Zhonghua Zhong Liu Za Zhi; 2008 Jul;30(7):545-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and prognostic factors in metachronous primary esophageal and gastric carcinomas].
  • OBJECTIVE: To investigate the clinical characteristics and prognostic factors in metachronous squamous cell carcinoma of the esophagus and gastric adenocarcinoma.
  • METHODS: From July 1979 to March 2005, 27 patients with metachronous carcinomas of the esophagus and stomach were treated, and the data were retrospectively reviewed.
  • The clinical features were analyzed, which included sex, age, family history of cancers, TNM stages of the gastric and esophageal carcinomas, resection mode, chemotherapy and/or radiotherapy, and the sequence of the two carcinomas taking place.
  • CONCLUSION: Metachronous squamous cell carcinoma of the esophagus and gastric adenocarcinoma show distinct clinical characteristics.
  • Surgical resection is mostly effective and the first choice of treatment.
  • [MeSH-major] Esophageal Neoplasms / surgery. Genetic Predisposition to Disease. Neoplasms, Second Primary / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / surgery. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Esophagectomy / methods. Female. Follow-Up Studies. Gastrectomy / methods. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062726.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Dietl B, Marienhagen J, Schaefer C, Pohl F, Kölbl O: [Frequency and distribution pattern of distant metastases in patients with ENT tumors and their consequences for pretherapeutic staging]. Strahlenther Onkol; 2007 Mar;183(3):138-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Häufigkeit und Topographie von Fernmetastasen bei Patienten mit HNO-Tumoren und ihre onsequenzen für das prätherapeutische Staging.
  • The distribution of primary tumor site and stage (AJCC) was as follows: oropharynx: n = 161 (26.8%), hypopharynx: n = 187 (31.2%), oral cavity: n = 89 (14.8%), larynx: n = 118 (19.7%), cancer of unknown origin: n = 13 (2.2%), others: n = 32(5.3%), I: n = 24 (4%), II: n = 49 (8.2%), III: n = 89 (14.8%), IV: n = 438 (73%).
  • The following parameters were analyzed in association with distant metastases: tumor localization, T- and N-category, primary treatment, local tumor control, and second neoplasms.
  • RESULTS: 114/600 patients (19%) developed distant metastases, 29/600 (4.9%) at presentation, 50% within 9.3 months after diagnosis of the primary tumor.
  • Distant metastases were most frequent in stage IV (24.2%), carcinoma of the hypopharynx (25.7%), local recurrence (24.3%), and second neoplasm (31.7%) with the following distribution pattern: pulmonary 61/114 (53.5%), pleural 15/114 (13.1%), osseous 45/114 (39.5%), hepatic 14/114 (12.3%), cerebral 8/114 (7%), cutaneous 14/114 (12.3%).
  • 82/600 (13.6%) patients additionally had second neoplasms, 20 corresponding with synchronous or metachronous bronchial tumors.
  • CONCLUSION: With locally advanced ENT tumor stage IVa/b, carcinoma of the hypopharynx, local recurrence or second neoplasms, at least a pretherapeutic CT of the thorax should be performed because every seventh patient (88/600) developed metastases or second primary tumors within the thoracic space during the course of disease.
  • Regarding the side effects and costs of curative therapy, the definition of generally accepted guidelines for the systemic staging of locally advanced ENT tumors should be undertaken.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Otorhinolaryngologic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Bronchogenic / pathology. Carcinoma, Bronchogenic / secondary. Combined Modality Therapy. Disease Progression. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Neoplasms, Second Primary / pathology. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17340072.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Turrini O, Guiramand J, Moutardier V, Viret F, Bories E, Giovannini M, Mokart D, Blache JL, Delpero JR: [Major hepatectomy for metastasis of colorectal cancer improves survival in the elderly]. Ann Chir; 2005 Oct;130(9):562-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHOD: Thirty-three consecutive patients aged over 70 years-old were treated in our institution for up to 3 resectable metachronous HMCC.
  • Fifteen patients had major LR (9 right hepatectomy, 3 extended right hepatectomy, 3 left hepatectomy) without pre or postoperative chemotherapy (group 1) and 18 patients were exclusively treated by chemotherapy (group 2) because of high ASA score (ASA 3) or patients refusal.
  • RESULTS: No patients died of another cause that colorectal cancer disease during observation time.
  • All patients of group 2 died during observation time.
  • High ASA score, multiple (more than 4) metastasis location, evolutive disease could justify an exclusive medical approach.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Morbidity. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202886.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Brega Massone PP, Lequaglie C, Conti B, Ferro F, Magnani B, Cataldo I: A particular case with long-term follow-up of rare malignant hemangiopericytoma of the lung with metachronous diaphragmatic metastasis. Thorac Cardiovasc Surg; 2002 Jun;50(3):178-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A particular case with long-term follow-up of rare malignant hemangiopericytoma of the lung with metachronous diaphragmatic metastasis.
  • The authors report the case of a woman with a primary hemangiopericytoma of the lung and successive metachronous diaphragmatic metastasis treated with surgery only according to the patient's decision.
  • One year later, a chest computed tomography (CT) scan showed a small lesion above the diaphragm on the left side.
  • A rethoracotomy to remove the metastatic diaphragmatic tumor was performed.
  • Chemotherapy with anthracycline and iphosphamide was proposed, but the patient again refused therapy for fear of side effects impairing another pregnancy.
  • Currently, the patient is alive and disease-free, 68 months after the first treatment.
  • [MeSH-major] Diaphragm / surgery. Hemangiopericytoma / secondary. Lung Neoplasms / pathology. Thoracic Neoplasms / secondary
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12077693.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Müller J, Kovács G, Jakab Z, Rényi I, Galántai I, Békési A, Kiss C, Nagy K, Kajtár P, Bartyik K, Masát P, Magyarosy E: [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary]. Orv Hetil; 2005 Jan 9;146(2):75-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary].
  • AIM: The aim of this study was to evaluate the experience with this protocol, the treatment results according to the risk groups and to compare the Hungarian data with the international results.
  • METHODS: Patients were stratified into 3 risk groups, based on initial white blood cell count, age, immunology, cytogenetics and response to treatment: standard, medium and high risk group.
  • Duration of the chemotherapy was 2 years, except of the boys in the standard risk group, their maintenance therapy was 1 year longer.
  • In one patient second malignancy occurred.
  • CONCLUSION: The treatment outcome of children with acute lymphoblastic leukemia improved remarkably over the last decades.
  • [MeSH-major] 6-Mercaptopurine / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisolone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Infant. Male. Remission Induction. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15724956.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin; ALL-BFM-95 protocol
  •  go-up   go-down


21. Avilés A, Neri N, Nambo MJ, Huerta-Guzman J, Cleto S: Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma. Med Oncol; 2006;23(2):295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma.
  • BACKGROUND AND OBJECTIVES: Treatment of high-grade MALT (mucosa-associated lymphoid tissue) gastric lymphoma remains uncertain.
  • To assess efficacy and toxicity of the most common therapies--surgery followed by chemotherapy or chemotherapy alone--we began a controlled clinical trial in patients in early stage (I and II 1).
  • METHODS: One hundred and two patients were randomized to be treated with surgery followed by six cycles of CEOP-Bleo (cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin at standard doses) (52 cases) or with chemotherapy alone (49 cases).
  • Actuarial curves at 5 yr showed that event-free survival were 70% (95% CI: 59-74%) in patients treated with surgery and chemotherapy, that were not statistically significant to 67% (95% CI: 51-69%) in the patients who received chemotherapy (p = 0.5).
  • Also, overall survival that was not statistically significant: 78% (95% CI: 70-88%) in the combined treatment and 76% (95% CI: 70-87%) in chemotherapy (p = 0.8).
  • No acute leukemia or second neoplasm has been observed.
  • CONCLUSIONS: The use of surgery and chemotherapy did not improve outcome in patients with early-stage high-grade gastric MALT lymphoma.
  • It is apparent that chemotherapy alone is sufficient treatment in this select group of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2002 May;55(5):346-51 [11986338.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3874-83 [11559725.001]
  • [Cites] Surgery. 1997 May;121(5):501-5 [9142147.001]
  • [Cites] Am J Surg. 2000 Mar;179(3):216-22 [10827324.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):12-8 [14679113.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] Haematologica. 2000 Apr;85(4):372-80 [10756362.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1466-74 [9136823.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] J Clin Pathol. 2000 Mar;53(3):187-90 [10823136.001]
  • [Cites] Gut. 1992 Oct;33(10):1307-11 [1446850.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):1020-9 [7927306.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1641-9 [11117785.001]
  • [Cites] Gastroenterology. 1991 Nov;101(5):1159-70 [1936785.001]
  • [Cites] J Surg Oncol. 2003 Jun;83(2):106-11 [12772204.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Ann Oncol. 1995 Apr;6(4):355-62 [7619750.001]
  • [Cites] Histopathology. 2002 Feb;40(2):117-26 [11952855.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • [Cites] Gut. 2001 Mar;48(3):297-303 [11171816.001]
  • (PMID = 16720930.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP-B protocol
  •  go-up   go-down


22. Ketata S, Boulaire JL, Soulimane B, Bargain A: Metachronous metastasis to the penis from a rectal adenocarcinoma. Clin Colorectal Cancer; 2007 Sep;6(9):657-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous metastasis to the penis from a rectal adenocarcinoma.
  • Penile metastases arise most frequently from genitourinary cancers, but can also arise from tumors of the large bowel; other primary sites are extremely uncommon.
  • The patient underwent palliative chemotherapy treatment with cetuximab/irinotecan.
  • Regardless of the treatment options, the prognosis of such metastasis remains poor.
  • [MeSH-major] Adenocarcinoma / secondary. Penile Neoplasms / secondary. Rectal Neoplasms / pathology
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cetuximab. Humans. Immunohistochemistry. Male. Middle Aged. Palliative Care. Prognosis

  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17945039.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 18
  •  go-up   go-down


23. Bornschein J, Rokkas T, Selgrad M, Malfertheiner P: Helicobacter pylori and clinical aspects of gastric cancer. Helicobacter; 2009 Sep;14 Suppl 1:41-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some modifications in the chemotherapies used for palliation and strategies for downstaging of the disease prior to surgical intervention are noteworthy.
  • The positive experience with endoscopic mucosal resection (EMR) and submucosal dissection (ESD) for treatment of early gastric cancer has been confirmed and extended.
  • The procedure-related morbidity and post-interventional quality of life is clearly favorable compared to open surgical resection in well-selected patients.
  • New data on Helicobacter pylori revealed that eradication after endoscopic resection of early gastric cancer significantly reduces the incidence of recurrent and metachronous gastric neoplasias.
  • It can further improve healing rates of treatment induced gastric ulcers.
  • Eradication therapy therefore remains the best target for prevention of the disease.
  • [MeSH-major] Helicobacter Infections. Helicobacter pylori / physiology. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19712167.001).
  • [ISSN] 1523-5378
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


24. Hakvoort-Cammel FG, Buitendijk S, van den Heuvel-Eibrink M, Hählen K: Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol. Pediatr Blood Cancer; 2004 Jul;43(1):8-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol.
  • BACKGROUND: To reduce radiotherapy (XRT) induced toxicity of treatment of children with Hodgkin disease (HD) while maintaining a high cure rate, we introduced a risk-adapted protocol consisting of chemotherapy (CT) alone in 1984.
  • PROCEDURE: The outcome of 46 children treated for HD from 1984 until 2000 according to the Rotterdam-HD-84-protocol was determined.
  • Children with stage I-IIA disease (n = 23), were treated with six courses of epirubicin, bleomycin, vinblastine, and dacarbazine (EBVD).
  • Children with stage IIB-IV disease (n = 23), were treated with three to five alternating cycles of EBVD and mechlorethamine, vincristine, procarbazine, and prednisone (MOPP).
  • RESULTS: At a median follow-up time of 8.6 years (range 2.6-18.3 years), the 10-year overall survival (OS) is 95% and the event-free survival (EFS) 91%.
  • Up until now only one patient developed hypothyroidism; no symptomatic cardiac or pulmonary dysfunction, no second malignancy has been diagnosed.
  • CONCLUSIONS: Risk-adapted treatment consisting of CT alone is highly efficacious for children with HD and toxicity is low.
  • CT should be the first choice for HD in children and XRT should preferably be used for those with refractory or histologically proven residual disease or relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Dacarbazine / therapeutic use. Epirubicin / therapeutic use. Hodgkin Disease / drug therapy. Mechlorethamine / therapeutic use. Prednisone / therapeutic use. Procarbazine / therapeutic use. Vinblastine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Netherlands / epidemiology. Statistics, Nonparametric. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15170884.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 3Z8479ZZ5X / Epirubicin; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; VB0R961HZT / Prednisone; EBVD protocol; MOPP protocol
  •  go-up   go-down


25. Küronya Z, Bodrogi I, Lövey J, Plótár V, Manninger S, Pápai Z: [Metachronous metastasis from rectal adenocarcinoma to the penis--case report]. Magy Onkol; 2009 Sep;53(3):263-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metachronous metastasis from rectal adenocarcinoma to the penis--case report].
  • The case of a 65-year-old man is presented: isolated penile metastasis discovered 4.5 years after the primary rectal cancer resection.
  • IHC tissue diagnosis and detailed clinical investigations confirmed metastatic rectal adenocarcinoma.
  • As our patient refused penectomy and KRAS mutation was proven, FOLFIRI chemotherapy was initiated without cetuximab.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Second Primary / diagnosis. Palliative Care / methods. Penile Neoplasms / secondary. Rectal Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cetuximab. Chemotherapy, Adjuvant. Diagnosis, Differential. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Organoplatinum Compounds / administration & dosage. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793691.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; Folfox protocol; IFL protocol
  •  go-up   go-down


26. Bacci G, Ferrari S, Longhi A, Donati D, Barbieri E, Forni C, Bertoni F, Manfrini M, Giacomini S, Bacchini P: Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. Oncol Rep; 2004 Jan;11(1):111-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy.
  • Although more and more patients with Ewing's sarcoma of bone (ESB) are being treated by surgery, the relative role of surgery and radiotherapy in the local treatment of this tumor has yet to be determined.
  • Because the outcome of ESB may differ according to the anatomical site of the tumor, results reported in the literature, which generally refer to series with tumors located in all sites, may be selection biased.
  • Chemotherapy was administered according to four sequentially activated protocols.
  • Two patients underwent only chemotherapy.
  • One hundred and fifty-two patients remained continuously free of disease, 108 relapsed, 2 died of chemotherapy toxicity and 6 developed a second malignancy.
  • Furthermore, in group 3 there were 6 secondary malignancies.
  • Our results indicate that surgery should always be considered in the local treatment of ES of the extremities.
  • Postoperative radiation therapy must be added in case of inadequate surgical margins.
  • [MeSH-major] Neoadjuvant Therapy / methods. Sarcoma, Ewing / surgery. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Extremities. Female. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14654912.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


27. Lordan JT, Karanjia ND: 'Close shave' in liver resection for colorectal liver metastases. Eur J Surg Oncol; 2010 Jan;36(1):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to investigate the effects of margin width on long-term survival after liver resection for CRLM with a policy of standard neo-adjuvant chemotherapy.
  • All patients with synchronous or early (<2 years) metachronous tumours were treated with neo-adjuvant chemotherapy.
  • A standard policy of neo-adjuvant chemotherapy may be associated with a low incidence of CIRM and improved long-term outcome of sub-centimetre margin widths, resembling those with >1cm resection margins.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19502001.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Ayyanar K, Blackman SC, Chordas C, Frazier L, Kieran MW: Metachronous mediastinal seminoma occurring after intracranial germinoma in an adolescent. J Pediatr Hematol Oncol; 2009 Nov;31(11):861-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous mediastinal seminoma occurring after intracranial germinoma in an adolescent.
  • Radiation therapy leads to the resolution of his pineal germinoma and normalization of the beta-HCG.
  • There was no evidence of recurrent central nervous system disease.
  • The patient underwent systemic chemotherapy with the complete resolution of the mediastinal seminoma.
  • [MeSH-major] Germinoma / radiotherapy. Mediastinal Neoplasms / drug therapy. Neoplasms, Second Primary / drug therapy. Pinealoma / radiotherapy. Seminoma / drug therapy
  • [MeSH-minor] Adolescent. Chorionic Gonadotropin, beta Subunit, Human / blood. Chorionic Gonadotropin, beta Subunit, Human / cerebrospinal fluid. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - Germinoma.
  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779380.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


29. Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, Stovall M, Frobisher C, Lancashire ER, Reulen RC, Hawkins MM: Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol; 2010 Dec 20;28(36):5287-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: CNS tumors are the most common second primary neoplasm (SPN) observed after childhood cancer in Britain, but the relationship of risk to doses of previous radiotherapy and chemotherapy is uncertain.
  • RESULTS: There were 137 meningiomas, 73 gliomas, and 37 other CNS neoplasms included in the analysis.
  • The risk of meningioma increased strongly, linearly, and independently with each of dose of radiation to meningeal tissue and dose of intrathecal methotrexate.
  • Those whose meningeal tissue received 0.01 to 9.99, 10.00 to 19.99, 20.00 to 29.99, 30.00 to 39.99 and≥40 Gy had risks that were two-fold, eight-fold, 52-fold, 568-fold, and 479-fold, respectively, the risks experienced by those whose meningeal tissue was unexposed.
  • The risk of glioma/primitive neuroectodermal tumors increased linearly with dose of radiation, and those who had CNS tissue exposed to at least 40 Gy experienced a risk four-fold that experienced by those who had CNS tissue unexposed.
  • CONCLUSION: The largest-ever study, to our knowledge, of CNS tumors in survivors of childhood cancer indicates that the risk of meningioma increases rapidly with increased dose of radiation to meningeal tissue and with increased dose of intrathecal methotrexate.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21079138.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010131-18; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS533866; NLM/ PMC4809645
  •  go-up   go-down


30. Hicks J, Flaitz C: Mucoepidermoid carcinoma of salivary glands in children and adolescents: assessment of proliferation markers. Oral Oncol; 2000 Sep;36(5):454-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant neoplasms represent one-third of all pediatric salivary gland tumors.
  • Mucoepidermoid carcinoma (MEC) composes 51% of malignant tumors and 16% of all salivary gland neoplasms in pediatrics.
  • Proliferation was assessed by determining the percentage of tumor cells immunoreactive for PCNA and Ki-67.
  • Tumor site was 16 parotid, eight submandibular, one base of tongue and one maxillary lip.
  • Median tumor size was 2.5 cm (range 1.5-5 cm).
  • Metastatic disease and capsular invasion occurred in five cases, while perineural invasion was noted in three cases.
  • Mean percentage of tumor cells immunoreactive for proliferation markers is as follows: PCNA: LG 9%, IG 17%, HG 32%; and Ki-67: LG 7%, IG 12%, HG 26%.
  • Treatment was surgical in 21 cases, and surgery with chemotherapy and radiotherapy in five cases.
  • Two patients with high grade MECs died of disease (21, 44 months).
  • Twenty-four patients had no evidence of disease at a median follow-up of 104 months (range 30-298 months).
  • MECs were second malignancies in two children with prior radiotherapy and chemotherapy for leukemia and histiocytosis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Mucoepidermoid / chemistry. Salivary Gland Neoplasms / chemistry
  • [MeSH-minor] Adolescent. Cell Division. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Ki-67 Antigen / chemistry. Male. Neoplasm Staging. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Retrospective Studies. Survival Analysis


31. Cho JY, Hong SJ: Autofluorescence imaging: as a new method for predicting metachronous gastric cancer. J Gastroenterol Hepatol; 2010 Dec;25(12):1814-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autofluorescence imaging: as a new method for predicting metachronous gastric cancer.
  • [MeSH-major] Endoscopy, Digestive System / methods. Fluorescence. Gastritis, Atrophic / pathology. Neoplasms, Second Primary. Stomach Neoplasms / pathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Biopsy. Early Detection of Cancer. Gastrectomy. Helicobacter Infections / drug therapy. Helicobacter Infections / microbiology. Helicobacter pylori / pathogenicity. Humans. Predictive Value of Tests. Risk Assessment. Risk Factors. Time Factors. Video Recording

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Gastroenterol Hepatol. 2010 Dec;25(12):1844-9 [21091995.001]
  • (PMID = 21091990.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


32. Dietl B, Marienhagen J, Schaefer C, Pohl F, Murthum T, Kölbl O: [Survival with distant metastatic disease in head and neck cancer. A retrospective analysis]. HNO; 2007 Oct;55(10):785-6, 788-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival with distant metastatic disease in head and neck cancer. A retrospective analysis].
  • [Transliterated title] Uberleben mit hämatogen metastasierten HNO-Tumoren: Eine retrospektive monozentrische Analyse.
  • QUESTIONS: The objective of this retrospective analysis was to investigate parameters with a potential impact on survival in a collective of 114 patients with distant metastatic disease after head and neck cancer.
  • PATIENTS AND METHODS: The primary endpoint was the survival with distant metastatic disease, the secondary endpoint was overall survival.
  • Primary therapy, local recurrence, second neoplasms, palliative chemotherapy (CHT) and radiotherapy (RT), as well as Karnofsky performance status (KPS) at the time of diagnosis of the metastases were analyzed as potential impact parameters using the log-rank test with subsequent Cox regression analysis.
  • RESULTS: Palliative CHT (P=0.0020) and KPS (P=0.0011) had a significant positive impact on the median survival probability with metastases (8.2 months) using the log-rank test, KPS at the time of diagnosis of metastases remained as an independent prognostic parameter in the Cox regression (P=0.0013).
  • Primary therapy, local tumor control and KPS had a significant positive influence on the median overall survival probability (18.5 months) univariately (P=0.0139, P=0.0106, P= 0.0096) and multivariately (P=0.0123, and P=0.0063, P=0.0197, respectively).
  • CONCLUSIONS: KPS at the time of diagnosis of metastases is an independent prognostic parameter for both endpoints.
  • Lacking evidence for life prolongation, palliative therapies should therefore first and foremost focus on the stabilization of the KPS.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / secondary. Palliative Care / statistics & numerical data. Risk Assessment / methods

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2005 Apr;32(2):156-64 [15815960.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):186-96 [15337555.001]
  • [Cites] Oncologist. 2000;5(3):199-208 [10884498.001]
  • [Cites] HNO. 2006 May;54(5):376-81 [16170507.001]
  • [Cites] HNO. 2006 Aug;54(8):589-90 [16826421.001]
  • [Cites] Radiother Oncol. 1995 Sep;36(3):198-202 [8532906.001]
  • [Cites] Laryngorhinootologie. 2006 Mar;85(3):172-8 [16547892.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1245-51 [1634913.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):257-63 [1732427.001]
  • [Cites] CA Cancer J Clin. 1995 Nov-Dec;45(6):352-68 [7583907.001]
  • [Cites] J Otolaryngol. 2006 Oct;35(5):332-7 [17049151.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Aug;5(4):667-86 [1890059.001]
  • [Cites] Acta Otorhinolaryngol Belg. 1999;53(3):247-52 [10635403.001]
  • [Cites] J Laryngol Otol. 1985 Nov;99(11):1131-42 [2414386.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):202-7 [11408812.001]
  • [Cites] Can J Oncol. 1996 Feb;6 Suppl 1:33-8 [8853536.001]
  • [Cites] Oral Oncol. 2004 May;40(5):525-31 [15006626.001]
  • [Cites] Onkologie. 2003 Dec;26(6):568-72 [14709932.001]
  • [Cites] Laryngoscope. 1994 Oct;104(10):1199-205 [7934588.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):378-81 [12902890.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):809-15 [15599859.001]
  • [Cites] HNO. 2005 Jun;53(6):511-2; discussion 512-4 [15902386.001]
  • [Cites] HNO. 2006 Aug;54(8):605-10 [16479384.001]
  • [Cites] Am J Clin Oncol. 2004 Oct;27(5):472-6 [15596913.001]
  • [Cites] Chest. 2005 Jun;127(6):2237-42 [15947343.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):543-7 [7918127.001]
  • [Cites] Acta Otolaryngol. 2005 Nov;125(11):1224-9 [16353407.001]
  • [Cites] Laryngoscope. 2000 Apr;110(4):593-602 [10764003.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 Feb;101(2 Pt 1):105-12 [1531402.001]
  • [Cites] Am J Clin Oncol. 1995 Aug;18(4):293-6 [7625368.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1119-26 [9869238.001]
  • [Cites] Acta Otolaryngol. 2005 Dec;125(12):1323-6 [16303682.001]
  • [Cites] Head Neck. 1999 May;21(3):204-10 [10208662.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):259-64 [11408825.001]
  • [Cites] BMC Cancer. 2006 Jan 31;6:28 [16448551.001]
  • [Cites] Semin Radiat Oncol. 2006 Jan;16(1):10-9 [16378902.001]
  • [Cites] Acta Otolaryngol. 2006 Apr;126(4):340-5 [16608783.001]
  • [Cites] Curr Probl Cancer. 1997 May-Jun;21(3):129-83 [9202888.001]
  • [Cites] Acta Otolaryngol. 2006 Oct;126(10 ):1096-103 [16923717.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):398-400 [9708641.001]
  • [Cites] Acta Otolaryngol. 2006 Sep;126(9):975-80 [16864497.001]
  • (PMID = 17333044.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Vázquez E, Lucaya J, Castellote A, Piqueras J, Sainz P, Olivé T, Sánchez-Toledo J, Ortega JJ: Neuroimaging in pediatric leukemia and lymphoma: differential diagnosis. Radiographics; 2002 Nov-Dec;22(6):1411-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent advances in therapy for pediatric hematologic neoplasms have greatly improved the prognosis but have resulted in an increased incidence of associated complications and toxic effects.
  • The main neuroimaging features in pediatric patients with leukemia or lymphoma treated with chemotherapy or radiation therapy were retrospectively reviewed.
  • To simplify the approach and facilitate differential diagnosis, the neuroimaging features have been classified into three main categories: central nervous system manifestations of primary disease, side effects of therapeutic procedures (radiation therapy, chemotherapy, bone marrow transplantation), and complications due to immunosuppression, particularly infections.
  • Manifestations of primary disease include cerebrovascular complications (hemorrhage, cerebral infarction) and central nervous system involvement (infiltration of the meninges, parenchyma, bone marrow, orbit, and spine).
  • Effects of radiation therapy include white matter disease, mineralizing microangiopathy, parenchymal brain volume loss, radiation-induced cryptic vascular malformations, and second neoplasms.
  • Effects of chemotherapy and bone marrow transplantation include hemorrhage, dural venous thrombosis, white matter disease, reversible posterior leukoencephalopathy syndrome, and anterior lumbosacral radiculopathy.
  • Both the underlying malignancy and antineoplastic therapy can cause immunosuppression.
  • Familiarity with the imaging findings is essential for proper diagnosis of neurologic symptoms in pediatric patients with oncohematologic disease.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Humans. Infant. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2002
  • (PMID = 12432112.001).
  • [ISSN] 0271-5333
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


34. Einhorn N, Tropé C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E: A systematic overview of radiation therapy effects in ovarian cancer. Acta Oncol; 2003;42(5-6):562-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic overview of radiation therapy effects in ovarian cancer.
  • A systematic review of radiation therapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU).
  • This synthesis of the literature on radiation therapy for ovarian cancer is based on data from six randomized trials.
  • No studies have been reported where adjuvant radiotherapy has been compared with no adjuvant therapy in early-stage, high-risk patients.
  • Adjuvant radiotherapy, either whole abdominal irradiation or intraperitoneal p32, has been compared with adjuvant chemotherapy in early-stage, high-risk patients.
  • There is some evidence to suggest that adjuvant radiotherapy after radical surgery leads to an increase in disease-free survival rate for patients with advanced-stage ovarian cancer.
  • There is little documentation on long-term side effects (second malignancy) after adjuvant radiotherapy and no conclusions can be drawn.
  • [MeSH-major] Brachytherapy / methods. Ovarian Neoplasms / mortality. Ovarian Neoplasms / radiotherapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Radiation. Female. Humans. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Sweden. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14596514.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 12
  •  go-up   go-down


35. Sausville JE, Hernandez DJ, Argani P, Gearhart JP: Pediatric renal cell carcinoma. J Pediatr Urol; 2009 Aug;5(4):308-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal cell carcinoma (RCC) comprises about 5% of pediatric renal neoplasms.
  • It has been recognized as a second malignancy in multiple reports.
  • It is generally symptomatic at diagnosis, and most children with RCC present with more locally advanced disease than do adults.
  • Contemporary investigation of pediatric RCC has demonstrated that a large percentage of these tumors bear cytogenetic translocations involving the MiT family of transcription factors.
  • Surgical therapy for these children resembles operative intervention for adult RCC, though debate continues about the precise role of lymph node dissection.
  • There are no adequately powered studies to support conclusions about adjuvant or neoadjuvant chemotherapy for children with RCC.
  • [MeSH-major] Carcinoma, Renal Cell. Kidney Neoplasms. Neoplasms, Second Primary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443274.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 45
  •  go-up   go-down


36. Laccourreye O, Veivers D, Bassot V, Ménard M, Brasnu D, Laccourreye H: Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with a platinum-based chemotherapy-alone regimen for cure. Ann Otol Rhinol Laryngol; 2002 Apr;111(4):315-21; discussion 321-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with a platinum-based chemotherapy-alone regimen for cure.
  • Based on an inception cohort of 35 patients with T1-3N0M0 squamous cell carcinoma of the true vocal cord who had a complete clinical response after a platinum-based induction chemotherapy regimen and a minimum of 3 years of follow-up, the current retrospective study documented the long-term results and consequences of local recurrence following the use of a platinum-based chemotherapy-alone regimen for cure.
  • During the years 1985 to 1996, 231 patients with invasive squamous cell carcinoma of the true vocal cord classified as T1-3N0M0 were managed at our department with a platinum-based induction chemotherapy regimen.
  • Thirty-five of the 77 patients with complete clinical response were managed at our institution with a platinum-based chemotherapy-alone regimen.
  • The statistical analysis of data on survival, local control, nodal control, distant metastasis, and metachronous second primary tumor incidence was based on the Kaplan-Meier product limit method.
  • Overall, the causes of death were intercurrent disease in 6 patients and metachronous second primary tumor in 4 patients.
  • Salvage treatment in patients with local recurrence yielded a 100% local control rate and laryngeal preservation rate.
  • The 5- and 10-year actuarial estimates for patients with metachronous second primary tumor were 9.7% and 28.1%, respectively.
  • Although local recurrence was noted in almost a third of patients with complete clinical response who were managed with a platinum-based chemotherapy-alone regimen, it did not appear to be detrimental, as none of the patients who had local recurrence ultimately died from their disease or lost their larynx.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local. Vocal Cords
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Chi-Square Distribution. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Otol Rhinol Laryngol. 2002 Sep;111(9):860 [12296346.001]
  • (PMID = 11991582.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


37. Murray RA, Thom G, Gardner RV, Craver RD: Infant acute lymphoblastic leukemia: a 20-year children's hospital experience. Fetal Pediatr Pathol; 2008;27(4-5):197-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • White blood cell counts ranged from 42,000-1.6 million/microL, 6 of 8 had hepatosplenomegaly, and 6 of 9 (66.6%) had central nervous system disease.
  • All received chemotherapy.
  • There were no late recurrences or second malignancies.
  • Despite extensive disease and age < 6 months at diagnosis (a poor prognostic feature), for ALL patients our 67% survival is at least as good as reported, although it is less favorable than childhood ALL.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hospitals, University. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning
  • [MeSH-minor] Acute Disease. Chromosomes, Human, Pair 11. Humans. Infant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18800262.001).
  • [ISSN] 1551-3823
  • [Journal-full-title] Fetal and pediatric pathology
  • [ISO-abbreviation] Fetal Pediatr Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Seidemann K, Henze G, Beck JD, Sauerbrey A, Kühl J, Mann G, Reiter A: Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol; 2000;11 Suppl 1:141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With improved management of infections, malignant disease is more frequently diagnosed and has become one of the commonest causes of death in pediatric AT and NBS.
  • PATIENTS AND METHODS: In three consecutive multicenter therapy trials for pediatric non-Hodgkin's lymphoma (NHL) (NHL-BFM), 1569 patients with newly diagnosed NHL have been registered between 1986 and 1997.
  • All patients received polychemotherapy according to tumor-entity and stage, none received radiation.
  • One patient died of toxic complications, two patients relapsed and died, one patient suffered from second malignancy.
  • Curative treatment is possible and should be attempted.
  • Intensity of therapy should be adjusted to individual risk factors and tolerance.

  • MedlinePlus Health Information. consumer health - Ataxia Telangiectasia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10707797.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


39. Lima EM, Leal MF, Burbano RR, Khayat AS, Assumpção PP, Bello MJ, Rey JA, Smith MA, Casartelli C: Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz J Med Biol Res; 2008 Jun;41(6):539-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric cancer is the forth most frequent malignancy and the second most common cause of cancer death worldwide.
  • Many tumor genes are inactivated by DNA methylation in gastric cancer.
  • We evaluated the DNA methylation status of ANAPC1, CDKN2A and TP53 by methylation-specific PCR in 20 diffuse- and 26 intestinal-type gastric cancer samples and 20 normal gastric mucosa in individuals from Northern Brazil.
  • Patients had never been submitted to chemotherapy or radiotherapy, nor did they have any other diagnosed cancer.
  • CDKN2A methylation was not detected in any normal gastric mucosa; however, the CDKN2A promoter was methylated in 30.4% of gastric cancer samples, with 35% methylation in diffuse-type and 26.9% in intestinal-type cancers.
  • CDKN2A methylation was associated with the carcinogenesis process for ~30% diffuse-type and intestinal-type compared to non-neoplastic samples.
  • CDKN2A can be implicated in the carcinogenesis process of only a subset of gastric neoplasias.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622497.001).
  • [ISSN] 1414-431X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / ANAPC1 protein, human; 0 / Apc1 Subunit, Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


40. Bertoni F, Bacchini P, Staals EL, Davidovitz P: Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer; 2005 Jun 1;103(11):2373-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dedifferentiated parosteal osteosarcoma (DPOS) is a variant of osteosarcoma in which a high-grade sarcoma coexists with a conventional parosteal osteosarcoma (c-POS), either at presentation (synchronous type) or at the time of recurrence (metachronous type).
  • The authors reviewed the clinical and radiologic features, histologic sections, treatments, and outcomes in this group of patients with DPOS.
  • One tumor involved the scapula, one involved the ilium, and another involved the skull.
  • Twenty-eight patients underwent surgery, and 18 of those patients received chemotherapy (5 patients received neoadjuvant chemotherapy, and 13 patients received adjuvant).
  • Of the nine patients who died, one patient received no treatment, five patients underwent surgery (with three patients achieving adequate margins) in combination with chemotherapy, and three patients underwent surgery only (with adequate margins achieved).
  • Of the 20 patients who remained alive, 13 patients underwent surgery (with 10 patients achieving adequate margins) in combination with chemotherapy, whereas 7 patients underwent surgery only (all with adequate margins).
  • One patient died of causes unrelated to the tumor, and another patient died shortly after undergoing resection of a lesion in the skull.
  • [MeSH-major] Bone Neoplasms / pathology. Cell Differentiation. Osteosarcoma, Juxtacortical / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852358.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


41. Yonemura Y, Kawamura T, Bando E, Takahashi S, Sawa T, Yoshimitsu Y, Obata T, Endo Y, Sasaki T, Sugarbaker PH: [Treatment results of peritoneal dissemination from gastric cancer by neoadjuvant intraperitoneal-systemic chemotherapy]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1723-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment results of peritoneal dissemination from gastric cancer by neoadjuvant intraperitoneal-systemic chemotherapy].
  • No standard treatment exists for peritoneal dissemination from gastric cancer.
  • We reviewed our experience using a novel treatment consisting of peritonectomy and intraoperative chemo-hyperthermic peritoneal perfusion (CHPP).
  • Peritoneal metastasis was synchronous in 75 and metachronous in 32 patients.
  • Seventeen patients (15%) were disease-free, and 90 patients were dead at the time of analysis.
  • Eighty-seven deaths were related to progression of disease.
  • Lymph node status, grade of peritoneal dissemination (P1-2 vs P3), age (>60 years vs <60 years), tumor volume of dissemination (>2.5 cm vs <2.5 cm in diameter), and histologic type (differentiated vs. poorly differentiated type) did not affect survival.
  • Patients who had an incomplete resection had 2.8-fold higher risk of dying from disease than patients who underwent complete cytoreduction.
  • This procedure is most appropriate for highly motivated patients who are committed to survive as long as possible.
  • [MeSH-major] Neoplasm Seeding. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Analysis of Variance. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Neoadjuvant Therapy. Peritoneum / surgery. Postoperative Complications. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553695.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Nurzyńska-Flak J, Mitura-Lesiuk M, Skomra S, Skomra D, Kowalczyk JR: [Second neoplasm in a 13-year-old boy complicated by Crohn's disease. Case report]. Med Wieku Rozwoj; 2004 Jul-Sep;8(3 Pt 2):839-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Second neoplasm in a 13-year-old boy complicated by Crohn's disease. Case report].
  • Genetic abnormalities and immune system disorders resulting from them are the causes of neoplastic diseases as well as inflammatory bowel disease, including Crohn's disease.
  • However, the rearrangement of genes may not only be the cause of neoplasms but also the result of oncolytic treatment used.
  • One of the late treatment-related complications of neoplastic diseases is the development of a second neoplasm and possible disorders belonging to the group of inflammatory bowel diseases, for example Crohn's disease.
  • The paper presents the case of a 13-year-old boy (K.G.) treated for a second neoplasm, complicated by Crohn's disease.
  • Eight years after the first line treatment the boy was diagnosed with the second neoplastic process -- pre-B acute lymphoblastic leukaemia (ALL-L2 pre-B common +).
  • On day 71 of the therapy, during aplasia of blood marrow following chemotherapy, inflammation of the caecum was diagnosed and metronidazole was introduced.
  • Once blood counts improved, the complaints decreased and with continued chemotherapy of Protocol M (mercaptopurine, methotrexate), completely subsided.
  • The histopathological evaluation of the sections demonstrated a typical picture of Crohn's disease.
  • Crohn's disease of the ileum was diagnosed, the treatment with dexamethazone (according to Protocol II) was instituted which led to complete regression of the iliac lesions.
  • Steroid therapy (prednisone) continued until the treatment supporting the remission according to Protocol ALLIC 2002 (mercaptopurine, methotrexate orally) was initiated.
  • CONCLUSION: The differential diagnosis of complications accompanying neoplasms should consider the inflammatory bowel diseases; their atypical course may be masked by the treatment of the underlying disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Crohn Disease / complications. Neoplasms, Second Primary / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Anti-Inflammatory Agents / therapeutic use. Dexamethasone / therapeutic use. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858256.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


43. Ogilvy-Stuart AL, Gleeson H: Cancer risk following growth hormone use in childhood: implications for current practice. Drug Saf; 2004;27(6):369-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The therapeutic use of growth hormone (GH) has caused concern, as it is anabolic and mitogenic, and its effector hormone, insulin-like growth factor (IGF)-I is anti-apoptotic.
  • As both hormones can cause proliferation of normal and malignant cells, the possibility that GH therapy may induce cancer, increase the risk of tumour recurrence in those previously treated for a malignancy, or increase the risk of cancer in those with a predisposition, has resulted in concerns over its use.
  • Malignant tumours have been induced in animals exposed to supraphysiological doses of GH, whereas hypophysectomy appears to protect animals from carcinogen-induced neoplasms.
  • A number of studies have been undertaken to determine the risk of the development of cancer in children treated with GH, either de novo, or the recurrence of cancer in those previously treated for a malignancy.
  • Even in children with a primary diagnosis of cancer, subsequent GH use does not appear to increase the risk of tumour recurrence.
  • In addition, follow-up of oncology patients has suggested an increase in second neoplasms in those who also received GH therapy.
  • [MeSH-major] Growth Hormone / adverse effects. Neoplasms / chemically induced
  • [MeSH-minor] Animals. Brain Neoplasms / chemically induced. Brain Neoplasms / epidemiology. Cell Division / drug effects. Child. Disease Models, Animal. Growth Disorders / therapy. Human Growth Hormone / adverse effects. Human Growth Hormone / therapeutic use. Humans. Insulin-Like Growth Factor Binding Protein 3 / metabolism. Insulin-Like Growth Factor I / metabolism. Leukemia / epidemiology. Leukemia / etiology. Neoplasm Recurrence, Local / chemically induced. Neoplasm Recurrence, Local / epidemiology. Risk Factors

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2816-21 [10946888.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jun;84(6):1961-5 [10372694.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Nov;80(11):3223-6 [7593429.001]
  • [Cites] J Womens Health Gend Based Med. 1999 Dec;8(10):1265-72 [10643834.001]
  • [Cites] J Pediatr. 1997 Jul;131(1 Pt 2):S32-6 [9255225.001]
  • [Cites] J Pediatr. 2003 May;142(5):539-45 [12756387.001]
  • [Cites] Cancer Detect Prev Suppl. 1987;1:149-57 [3480049.001]
  • [Cites] Science. 1957 Jan 25;125(3239):158-60 [13390981.001]
  • [Cites] Arch Intern Med. 1991 Aug;151(8):1629-32 [1678593.001]
  • [Cites] Lancet. 1988 Mar 19;1(8586):642 [2894566.001]
  • [Cites] J Clin Endocrinol Metab. 1996 May;81(5):1704-10 [8626820.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1072-6 [10713692.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2033-41 [11994337.001]
  • [Cites] Eur J Pediatr. 1989 Jun;148(7):591-6 [2663511.001]
  • [Cites] Child Nephrol Urol. 1990;10(2):72-5 [2253254.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2803-7 [8168113.001]
  • [Cites] Transplant Proc. 1975 Jun;7(2):327-31 [236612.001]
  • [Cites] Cancer. 1991 May 1;67(9):2280-3 [2013034.001]
  • [Cites] Pediatr Hematol Oncol. 1991 Jan-Mar;8(1):77-82 [2029469.001]
  • [Cites] Lancet. 1977 Aug 27;2(8035):434-5 [70647.001]
  • [Cites] South Med J. 1983 Sep;76(9):1181-2 [6612402.001]
  • [Cites] Recent Prog Horm Res. 1975;31:141-74 [172992.001]
  • [Cites] BMJ. 1998 Apr 11;316(7138):1132-3 [9552951.001]
  • [Cites] Horm Res. 2000;53 Suppl 3:53-6 [10971105.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1509-11 [8603394.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Dec;47(6):647-8 [9497869.001]
  • [Cites] Br J Cancer. 1997;76(9):1115-8 [9365156.001]
  • [Cites] Horm Res. 1997;48 Suppl 4:29-32 [9350443.001]
  • [Cites] Clin Transpl. 1990;:53-62 [2103172.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2744-51 [9389738.001]
  • [Cites] Growth Horm IGF Res. 2000 Apr;10 Suppl A:S47-8 [10984292.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):394-9 [1999709.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2959-64 [12089225.001]
  • [Cites] Science. 1998 Jan 23;279(5350):563-6 [9438850.001]
  • [Cites] JAMA. 1993 Dec 15;270(23):2829-32 [8133622.001]
  • [Cites] Ann N Y Acad Sci. 1958 Oct 7;73(3):635-53 [13617872.001]
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):1-6 [10579905.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):620-5 [10203281.001]
  • [Cites] Ann Intern Med. 1991 May 1;114(9):754-5 [2012357.001]
  • [Cites] Blut. 1973 Jan;26(1):74-81 [4734249.001]
  • [Cites] BJU Int. 2000 Mar;85(4):559-60 [10766527.001]
  • [Cites] Acta Paediatr Suppl. 1995 Sep;411:41-4 [8563068.001]
  • [Cites] Eur J Endocrinol. 2002 Nov;147(5):625-33 [12444894.001]
  • [Cites] Blood. 1988 Jul;72(1):66-72 [3291986.001]
  • [Cites] Pediatr Hematol Oncol. 1993 Jan-Mar;10(1):55-62 [8443053.001]
  • [Cites] Cancer Res. 1990 Jan 1;50(1):48-53 [2152773.001]
  • [Cites] Lancet. 1987 Mar 28;1(8535):711-3 [2882131.001]
  • [Cites] J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):237-42 [1525063.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Sep;53(3):329-36 [10971450.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1499-504 [7906609.001]
  • [Cites] Am J Gastroenterol. 1985 Apr;80(4):266-9 [3984995.001]
  • [Cites] Lancet. 1998 May 9;351(9113):1393-6 [9593409.001]
  • [Cites] BJU Int. 2000 Jan;85(1):125-9 [10619960.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Oct;49(4):441-5 [9876340.001]
  • [Cites] BMJ. 1991 Apr 6;302(6780):824-8 [2025705.001]
  • [Cites] Am J Physiol. 1992 Mar;262(3 Pt 2):R426-31 [1373040.001]
  • [Cites] Horm Metab Res. 1994 Feb;26(2):81-4 [8200618.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3064-70 [10487666.001]
  • [Cites] Transplantation. 1995 Feb 27;59(4):480-5 [7878750.001]
  • [Cites] Nature. 1974 Dec 20;252(5485):747-8 [4548160.001]
  • [Cites] Am J Dis Child. 1985 Apr;139(4):347-50 [3976624.001]
  • [Cites] Q J Med. 1970 Jan;39(153):1-16 [5427331.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4444-9 [11134091.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Jan;32(1):65-71 [2331812.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 20;91(2):151-6 [9923856.001]
  • [Cites] BMJ. 1992 Jun 20;304(6842):1601-5 [1628087.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Nov;41(5):597-601 [7828348.001]
  • [Cites] Cancer Res. 1950 May;10(5):297-308 [15414480.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):911-5 [9637140.001]
  • [Cites] Gut. 2000 Mar;46(3):440-1 [10733316.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12181-8 [9115291.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):273-7 [12147369.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(1):21-30 [10647497.001]
  • [Cites] Endocrinology. 1987 May;120(5):1806-12 [3569112.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Apr;80(4):1416-22 [7714117.001]
  • [Cites] Cancer Res. 1956 Feb;16(2):111-6 [13293649.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3136-41 [12107213.001]
  • [Cites] Cancer. 1991 Oct 15;68(8):1673-7 [1913507.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jul;77(1):229-33 [7686915.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):592-8 [10404076.001]
  • [Cites] Endocr Rev. 2000 Jun;21(3):215-44 [10857553.001]
  • [Cites] Eur J Pediatr. 1987 May;146(3):257-60 [3474148.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jan;23(1):39-44 [11196268.001]
  • [Cites] Blood. 1981 Aug;58(2):337-40 [6972789.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2730-4 [9709939.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):437-8 [3408064.001]
  • [Cites] Pediatr Res. 1999 Oct;46(4):435-9 [10509364.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):480-7 [11208842.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):532-4 [10639112.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Sep;71(3):688-95 [2394775.001]
  • (PMID = 15144231.001).
  • [ISSN] 0114-5916
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 3; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  • [Number-of-references] 98
  •  go-up   go-down


44. Ng TY, Wong LC: Diagnosis and management of gestational trophoblastic neoplasia. Best Pract Res Clin Obstet Gynaecol; 2003 Dec;17(6):893-903
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of gestational trophoblastic neoplasia.
  • The FIGO Committee Report on the FIGO 2000 staging for gestational trophoblastic disease included criteria for the diagnosis of gestational trophoblastic neoplasia (GTN).
  • The use of single agent chemotherapy for low-risk disease versus multi-agent chemotherapy for high-risk disease is discussed.
  • Controversies regarding when to stop chemotherapy are explored with a view to minimizing the short and long-term toxicity, in particular the small risk of developing a second malignancy.
  • Recommendations for the follow up of patients after chemotherapy with particular reference to contraceptive advice and future pregnancies are discussed in the light of current evidence.
  • [MeSH-major] Gestational Trophoblastic Disease / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin / blood. Contraception. Female. Fertility. Humans. Neoplasm Metastasis. Neoplasm Staging. Practice Guidelines as Topic. Pregnancy. Reagent Kits, Diagnostic. Risk Factors. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614888.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin; 0 / Reagent Kits, Diagnostic
  • [Number-of-references] 21
  •  go-up   go-down


45. Seo DB, Kwon KS, Park HS, Lee DH, Kim HG, Shin YW, Kim YS, Kim JM: Metachronous gastric MALT lymphoma and early gastric cancer: a case report. Korean J Gastroenterol; 2007 Apr;49(4):245-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous gastric MALT lymphoma and early gastric cancer: a case report.
  • Metachronous association between gastric lymphoma and early gastric cancer is a rare event.
  • Recent studies have suggested that a relationship exists between gastric mucosa-associated lymphoid tissue (MALT) lymphoma and gastric carcinoma although the mechanism is unknown.
  • The patient received anti-Helicobacter pylori eradication therapy, followed by 6 cycles of chemotherapy and radiation therapy, and achieved complete remission 12 months after the therapy.
  • To the best of our knowledge, this is the first case report of metachronous MALT lymphoma and subsequent gastric carcinoma in Korea.
  • [MeSH-major] Gastric Mucosa / pathology. Lymphoma, B-Cell, Marginal Zone / diagnosis. Neoplasms, Second Primary / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Endoscopy, Digestive System. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17464170.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


46. Takagi T, Nakase Y, Fukumoto K, Miyagaki T, Ishida E, Kobayashi Y, Soga K, Kanemitsu D, Kassai K, Sakamoto K, Takenaka S, Yanagida K, Itani K, Fukumoto I: [Long-term disease-free survival following multimodal treatment in a patient with curatively unresectable advanced gastric cancer with metachronous liver metastasis]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2421-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term disease-free survival following multimodal treatment in a patient with curatively unresectable advanced gastric cancer with metachronous liver metastasis].
  • Despite a diagnosis of cStage IV gastric cancer (cN2, cH0, cM0, cT3 (SE), cP1), we preferentially performed a non-curative surgery to avoid stenosis or bleeding by tumor invasion.
  • Since no evidence of peritoneal metastasis was found at surgery, distal gastrectomy with D2 lymph node dissection was performed, and lymph nodes anterior to the pancreatic head were sampled.
  • The pathological diagnosis was pT3 (SE), pN2, sH0, pM1 (LYM), pStage IV.
  • We speculate that in the presence of N or M (LYM) factors for stage IV gastric cancer, surgery with lymphadenectomy, which does not prevent the completion of adjuvant chemotherapy, followed by multimodal treatments such as continued chemotherapy and RFA, led to the long-term survival.
  • [MeSH-major] Liver Neoplasms / secondary. Neoplasms, Second Primary / secondary. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Catheter Ablation. Combined Modality Therapy. Disease-Free Survival. Drug Combinations. Gastrectomy. Humans. Lymph Node Excision. Male. Middle Aged. Oxonic Acid / therapeutic use. Tegafur / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224593.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


47. Franklin M, Trevino J, Hernandez-Oaknin H, Fisher T, Berghoff K: Laparoscopic hepatic artery catheterization for regional chemotherapy: is this the best current option for liver metastatic disease? Surg Endosc; 2006 Apr;20(4):554-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic hepatic artery catheterization for regional chemotherapy: is this the best current option for liver metastatic disease?
  • BACKGROUND: Metastatic disease isolated to the liver is present at the time of diagnosis in 20-30% of patients with colorectal cancer.
  • Systemic chemotherapy remains the primary treatment modality for such patients.
  • The morbidity associated with regional chemotherapy is largely a result of the laparotomy required to place a hepatic arterial infusion pump in these debilitated patients.
  • We discuss the main advantages of laparoscopic approach in comparison to both open procedure and percutaneous hepatic artery catheterization.
  • 24 patients (88.8%) had bilobar disease precluding surgical resection of the liver metastases.
  • Postoperatively, 16 patients (59.2%) had hepatic intra-arterial chemotherapy in the recovery room as a preplanned protocol.
  • 22 patients with residual hepatic disease, in whom chemotherapy was successfully instituted, showed regression of their metastases, in 18 patients, CEA had improved at their one-month follow-up visit.
  • CONCLUSIONS: In experienced hands, laparoscopic hepatic artery catheterization is a safe, feasible and minimally invasive technique for those patients with metachronous liver malignancies.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Catheterization / methods. Catheters, Indwelling. Colorectal Neoplasms / pathology. Hepatic Artery. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary


48. Ueda K, Kaneda Y, Sakano H, Tanaka T, Saito K, Hamono K: Successful treatment of intracardiac progression and metachronous multiple brain metastases from primary lung cancer. Jpn J Thorac Cardiovasc Surg; 2006 Apr;54(4):168-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of intracardiac progression and metachronous multiple brain metastases from primary lung cancer.
  • The tumor tissue including the thrombus was resected en-bloc under cardiopulmonary bypass.
  • Despite adjuvant chemotherapy, multiple brain metastases developed, but they were eradicated by stereotactic radiosurgery.
  • The patient is still disease-free 48 months after the resection.
  • This case serves to demonstrate the validity of multidisciplinary treatment for locally advanced lung cancer.
  • [MeSH-major] Brain Neoplasms / surgery. Carcinoma, Squamous Cell / therapy. Heart Neoplasms / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Neoplasms, Second Primary / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cardiopulmonary Bypass. Chemotherapy, Adjuvant. Female. Heart Atria / pathology. Heart Atria / surgery. Humans. Pulmonary Veins / pathology. Pulmonary Veins / surgery. Radiosurgery. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CNS Drugs. 2002;16(5):325-38 [11994022.001]
  • [Cites] Int Surg. 1990 Jan-Mar;75(1):22-6 [2156780.001]
  • [Cites] Chest. 1972 Oct;62(4):444-6 [5078000.001]
  • [Cites] Lung Cancer. 2003 Sep;41(3):333-43 [12928124.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):476-9 [12393988.001]
  • [Cites] J Thorac Cardiovasc Surg. 1984 Aug;88(2):189-92 [6748712.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1276-81 [12507123.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):499-506 [12507085.001]
  • (PMID = 16642924.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


49. Kayıran SM, Özbek N: Acute Monoblastic Leukemia as a Second Malignancy After Doxorubicin and Cisplatin Treatment for Osteosarcoma. Turk J Haematol; 2003 Mar 5;20(1):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute Monoblastic Leukemia as a Second Malignancy After Doxorubicin and Cisplatin Treatment for Osteosarcoma.
  • Secondary or therapy-related acute myeloid leukemia (t-AML) occurs as a complication of various chemotherapy regimens.
  • In pediatric age group, leukemia as a second malignancy after osteosarcoma treatment with doxorubicin and cisplatin is relatively rare.
  • We interpreted this as a rare case of t- AML with normal cytogenetic analysis, and believe the disease was induced by the addition of platinum compounds to a regimen including topoisomerase II inhibitors.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265334.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


50. Fernando IN: The role of radiotherapy in patients undergoing mastectomy for carcinoma of the breast. Clin Oncol (R Coll Radiol); 2000;12(3):158-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of recurrences will occur in the first 5 years and 50% of patients will have metastatic disease at the time of recurrence.
  • Improvements in breast cancer mortality may however be counterbalanced by increases in cardiac events and deaths caused by second malignancies.
  • Adjuvant radiation combined with systemic chemotherapy has a significant effect on local recurrence and probably on survival in node-positive patients after mastectomy.
  • Controversy still exists about what fields should be irradiated and in particular whether the supraclavicular fossa and internal mammary node chain should be included in adjuvant therapy.
  • Treatment at relapse on the chest wall may require a combination of surgery, radiotherapy and chemotherapy, depending on previous therapy.
  • Re-irradiation after radical adjuvant radiotherapy can be considered only for selected patients when an adequate discussion with them has taken place with regard to the relative benefits versus toxicity.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma / radiotherapy. Carcinoma / surgery. Mastectomy
  • [MeSH-minor] Anticarcinogenic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10942332.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 55
  •  go-up   go-down


51. Nwaorgu OG, Onakoya PA: Inverted papilloma of the nose and paranasal sinuses: a fifteen-year review. Afr J Med Med Sci; 2002 Sep;31(3):191-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inverted papilloma is a relatively rare epithelial neoplasm of the nose and paranasal sinuses accounting for 0.5-4% of all primary tumours of the nose.
  • There was associated synchronous and metachronous squamous cell carcinoma (SCC) in two patients respectively.
  • Nine patients had conservative surgery (intranasal clearance/antrostomy and external fronto-ethmoidectomy) while the remaining six patients had radical surgery (lateral rhinotomy/medial maxillectomy) at various times.
  • The two patients with SCC had adjunct radiotherapy/chemotherapy in addition.
  • We therefore advocate radical surgery in our environment as the treatment of choice for effective limitation of recurrence.
  • [MeSH-major] Nose Neoplasms / epidemiology. Nose Neoplasms / pathology. Papilloma, Inverted / epidemiology. Papilloma, Inverted / pathology. Paranasal Sinus Neoplasms / epidemiology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Antineoplastic Agents / therapeutic use. Biopsy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Chemotherapy, Adjuvant. Female. Hospitals, University. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / pathology. Nigeria / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Sex Distribution. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12751555.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


52. Chang WC, Sheu BC, Chen RC, Chow SN, Huang SC: Depressed host immunity in a case of metachronous primary uterine papillary serous carcinoma and non-Hodgkin's lymphoma. Int J Gynecol Cancer; 2004 Sep-Oct;14(5):1030-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depressed host immunity in a case of metachronous primary uterine papillary serous carcinoma and non-Hodgkin's lymphoma.
  • Metachronous primary malignant tumors of uterine papillary serous carcinoma (UPSC) and non-Hodgkin's lymphoma (NHL) are rare.
  • We describe the clinical features of a 63-year-old patient with UPSC that was found 2 years after chemotherapy for malignant lymphoma of neck, stage IV and 5 months after radiation therapy for recurrence.
  • One month after completion of radiotherapy, the patient expired due to persistence of the disease.
  • Immunological profile of this patient stressed the issue of depressed host immunity and associated malignancies.
  • [MeSH-major] Carcinoma, Papillary / immunology. Carcinoma, Papillary / pathology. Immunocompromised Host. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Neoplasms, Second Primary / immunology. Neoplasms, Second Primary / pathology. Uterine Neoplasms / immunology. Uterine Neoplasms / pathology
  • [MeSH-minor] Disease Progression. Female. Flow Cytometry. Humans. Killer Cells, Natural. Middle Aged. T-Lymphocytes

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15361220.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. van Halteren HK, Peters HM, van Krieken JH, Coebergh JW, Roumen RM, van der Worp E, Wagener JT, Vreugdenhil G: Tumor growth pattern and thymidine phosphorylase expression are related with the risk of hematogenous metastasis in patients with Astler Coller B1/B2 colorectal carcinoma. Cancer; 2001 May 1;91(9):1752-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor growth pattern and thymidine phosphorylase expression are related with the risk of hematogenous metastasis in patients with Astler Coller B1/B2 colorectal carcinoma.
  • BACKGROUND: The benefit of adjuvant chemotherapy appears to be limited for patients with Astler Coller B1/B2 colorectal carcinoma but may be better in a subgroup of patients with a high recurrence risk.
  • From this database, all patients with an Astler Coller B1 or B2 tumor who subsequently had developed hematogenous metastases were taken as cases.
  • For each case, three matched controls (age, Astler Coller, year of diagnosis) without metachronous metastases were selected.
  • Tumor growth pattern and tumor TP expression both independently contributed to recurrence risk.
  • CONCLUSIONS: Tumor growth pattern and degree of TP expression both appear to be related to the recurrence risk.
  • Prospective trials should point out whether these variables can be implemented in the decision making concerning adjuvant chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / pathology. Hematologic Neoplasms / enzymology. Thymidine Phosphorylase / metabolism
  • [MeSH-minor] Case-Control Studies. Humans. Neoplasm Metastasis. Neoplasm Recurrence, Local / epidemiology. Risk Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11335901.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


54. Hall GW, Katzilakis N, Pinkerton CR, Nicolin G, Ashley S, McCarthy K, Daw S, Hewitt M, Wallace WH, Shankar A: Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report. Br J Haematol; 2007 Sep;138(6):761-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In both trials, only patients with stage IA disease had the option of being treated with either involved field radiation alone or combination chemotherapy consisting of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP).
  • Patients with all other stages were treated with ChlVPP chemotherapy.
  • Thirty-five patients (83%) presented with early stage disease (Stages I & II).
  • Six children relapsed after primary therapy.
  • There have been no second malignancies or transformations to B-cell non-Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Chlorambucil / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Great Britain. Humans. Ireland. Male. Prednisone / therapeutic use. Procarbazine / therapeutic use. Prospective Studies. Recurrence. Remission Induction. Survival Rate. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760808.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; 35S93Y190K / Procarbazine; 5V9KLZ54CY / Vinblastine; VB0R961HZT / Prednisone; CHIVPP protocol
  •  go-up   go-down


55. Sugimoto K, Nakahara I, Nishikawa M: Bilateral metachronous germinoma of the basal ganglia occurring long after total removal of a mature pineal teratoma: case report. Neurosurgery; 2002 Mar;50(3):613-6; discussion 616-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral metachronous germinoma of the basal ganglia occurring long after total removal of a mature pineal teratoma: case report.
  • OBJECTIVE AND IMPORTANCE: We report the extremely rare occurrence of a second germ cell tumor at a different site and with different histological types long after total removal of a mature pineal teratoma.
  • Neuroradiological studies revealed a tumor in the pineal region.
  • The tumor was totally removed.
  • Histologically, the tumor proved to be a mature teratoma.
  • The patient received no adjuvant therapy and was followed in the outpatient clinic.
  • Neuroradiological studies showed a tumor in the bilateral basal ganglia.
  • INTERVENTION: The second tumor, which was located in the right basal ganglion, was partially removed for biopsy.
  • Histologically, the tumor proved to be a germinoma.
  • The patient received three cycles of combination chemotherapy consisting of carboplatin and etoposide with radiotherapy.
  • After the second course of chemotherapy, magnetic resonance imaging studies revealed no evidence of the tumor.
  • CONCLUSION: The second tumor was considered to be a de novo metachronous neoplasm rather than a recurrence of the original mature teratoma.
  • We think that if primordial germ cell groups exist along the midline of the brain, more than two primordial germ cell groups could give rise to metachronous neoplasms at different sites and with different histological types.
  • [MeSH-major] Basal Ganglia Diseases / surgery. Brain Neoplasms / surgery. Germinoma / surgery. Neoplasms, Second Primary. Pineal Gland / surgery. Teratoma / surgery
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Child. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Germinoma.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11841731.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  • [Number-of-references] 11
  •  go-up   go-down


56. Miser JS, Goldsby RE, Chen Z, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore SG, Rausen AR, Vietti TJ, Grier HE: Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group. Pediatr Blood Cancer; 2007 Dec;49(7):894-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group.
  • BACKGROUND: The outcome for patients with Ewing sarcoma family of tumors (ESFTs) of bone with metastases at diagnosis remains poor despite new approaches to treatment.
  • We evaluated whether a dose-intensity chemotherapy regimen improved survival for patients with ESFTs of bone with metastases at diagnosis.
  • METHODS: We entered 60 patients with metastatic ESFTs of bone onto a single arm trial of a new intensive therapy.
  • Treatment consisted of 51-weeks of chemotherapy and local control of the primary with radiation, surgery, or both.
  • The chemotherapeutic protocol included two alternating blocks: one with vincristine (2 mg/m(2)), doxorubicin (90 mg/m(2)), and cyclophosphamide (2,200 mg/m(2)); and the second with ifosfamide (2,800 mg/m(2)/day x 5 days) and etoposide (100 mg/m(2)/day x 5 days).
  • Six patients (6-year cumulative incidence: 9%) developed second malignant neoplasms and died.
  • The 6-year overall event-free survival (EFS) was 28% (standard error (SE) 6%) and survival (S) was 29% (SE 6%).
  • CONCLUSION: An intensified treatment regimen using higher doses of cyclophosphamide, ifosfamide, and doxorubicin increased toxicity and risk of second malignancy without improving EFS and S.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Neoplasms, Second Primary / chemically induced. Neuroectodermal Tumors, Primitive / therapy. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Critical Care. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Injections, Subcutaneous. Male. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17584910.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA 13539; United States / NCI NIH HHS / CA / U10 CA 30969; United States / NCI NIH HHS / CA / U10 CA 98543
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


57. Yoda Y, Yoshino T, Kadowaki S, Bando H, Okano S, Fukushima H, Fuse N, Tahara M, Doi T, Ohtsu A: [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy]. Gan To Kagaku Ryoho; 2009 Jun;36(6):1003-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].
  • We reported two cases of unresectable or recurrent colorectal cancer effectively treated by cetuximab after the progression of the prior chemotherapy.
  • He received cetuximab plus irinotecan combination therapy in the third-line setting.
  • Amonth after the initiation of the chemotherapy, abdominal CT showed tumor shrinkage of liver metastases.
  • Case 2: A57-year-old female suffered from sigmoid colon cancer with metachronous liver, ovarian metastases, ascites and pleural effusion.
  • Five weeks after initiation of chemotherapy, her chest, abdominal and pelvic CT showed tumor shrinkage of the liver metastases and the reduction of both ascites and pleural effusion, together with resolution of her dyspnea on exertion.
  • Before cetuximab administration, we investigated KRAS status on cancer tissue previously resected in the above 2 cases, which showed KRAS wild-type.
  • Cetuximab could be effective for KRAS wild-type colorectal cancer, as well as the previous reports from Western countries.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy. Proto-Oncogene Proteins / genetics. ras Proteins / genetics
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cetuximab. Female. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542725.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 7673326042 / irinotecan; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


58. Masannat YA, Peter M, Turton P, Shaaban AM: Case report of bilateral inflammatory breast cancer. Eur J Cancer Care (Engl); 2010 Jul;19(4):558-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report an unusual case of bilateral metachronous IBC each with complete clinico-pathological response after treatment with neoadjuvant chemotherapy and surgery on both occasions.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Inflammatory Breast Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Middle Aged. Neoadjuvant Therapy. Treatment Outcome


59. van der Pool AE, Lalmahomed ZS, Ozbay Y, de Wilt JH, Eggermont AM, Jzermans JN, Verhoef C: 'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome. Colorectal Dis; 2010 Oct;12(10 Online):e229-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome.
  • The features and prognosis of patients with synchronous and metachronus colorectal liver metastases, treated with primary resection first followed by partial liver resection were analysed.
  • Demographics, characteristics of the primary tumour and metastatic tumours, surgery-related data and outcome were analysed.
  • RESULTS: Synchronous metastases were present in 105 (39%) patients and metachronous metastases in 167 (61%).
  • More patients in the synchronous group had an advanced primary tumour (T3/T4 and/or node positivity), more than three liver metastases and bilobar distribution.
  • A significantly higher percentage of patients in the synchronous group received neoadjuvant chemotherapy.
  • There were no differences in disease-free and overall survival rates between the synchronous and metachronous group.
  • CONCLUSION: Although patients with synchronous colorectal liver metastases may have poorer biological features, there was no difference in 5-year disease-free and overall survival compared with patients with metachronous metastases.
  • This may be explained by the observation that patients in the synchronous group received significantly more neoadjuvant chemotherapy.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatectomy. Humans. Male. Middle Aged. Neoadjuvant Therapy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Colorectal Disease © 2010 The Association of Coloproctology of Great Britain and Ireland.
  • (PMID = 19912286.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Venkateswaran V, Klotz LH, Fleshner NE: Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res; 2002 May 1;62(9):2540-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostate cancer (PCA) is the most common histological malignancy and the second leading cause of cancer deaths among North American men.
  • Treatment with selenium caused G1 arrest and an 80% reduction in the S phase of LNCaP with no effect on PC3.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Cycle Proteins / metabolism. Cyclins / metabolism. Prostatic Neoplasms / pathology. Selenium / pharmacology. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Cell Cycle / drug effects. Cell Division / drug effects. Cyclin-Dependent Kinase Inhibitor p21. Cyclin-Dependent Kinase Inhibitor p27. G1 Phase / drug effects. Growth Inhibitors / pharmacology. Humans. Male. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / genetics. Neoplasms, Hormone-Dependent / metabolism. Neoplasms, Hormone-Dependent / pathology. Receptors, Androgen / biosynthesis. Receptors, Androgen / genetics. Receptors, Androgen / physiology. Transfection

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11980647.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Growth Inhibitors; 0 / Receptors, Androgen; 0 / Tumor Suppressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; H6241UJ22B / Selenium
  •  go-up   go-down


61. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T: Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol; 2000 Sep;110(3):577-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
  • However, the relatively short follow-up (median 27 months) did not enable the evaluation of the risk of developing secondary malignancies.
  • In this study, we report the long-term outcome of the 114 patients included in the trial: 56 patients randomized to receive HU and 58 patients to receive no cytoreductive therapy.
  • Analysis was by intention to treat and, when indicated, by treatment.
  • Seven patients (13%) in the HU group developed secondary acute leukaemia, myelodysplastic syndromes or solid tumours, compared with only one of the control group patients (1.7%) (P = 0.032).
  • The occurrence of secondary malignancies was also analysed by treatment: none of the 20 patients who had never been treated with chemotherapy developed neoplasia vs. three of the 77 patients given HU only (3.9% n.s.) and five of the 15 patients given busulphan plus HU (33% P < 0. 0001).
  • (b) the sequential use of busulphan and HU significantly increased the risk of second malignancies; and (c) overall survival was not affected by HU therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Busulfan / therapeutic use. Hydroxyurea / therapeutic use. Neoplasms, Second Primary / chemically induced. Thrombocythemia, Essential / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Leukemia / chemically induced. Male. Middle Aged. Myelodysplastic Syndromes / chemically induced. Thrombosis / prevention & control

  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. BUSULFAN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2002 Mar;116(4):923-4 [11886403.001]
  • (PMID = 10997967.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] G1LN9045DK / Busulfan; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


62. Longhi A, Pasini E, Bertoni F, Pignotti E, Ferrari C, Bacci G: Twenty-year follow-up of osteosarcoma of the extremity treated with adjuvant chemotherapy. J Chemother; 2004 Dec;16(6):582-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty-year follow-up of osteosarcoma of the extremity treated with adjuvant chemotherapy.
  • We have updated the results of an adjuvant chemotherapy study of 106 patients with osteosarcoma of the extremities published 17 years ago, treated by surgery followed by adjuvant chemotherapy with vincristine (VCR), methotrexate (MTX) and doxorubicin (ADM), between 1980-1983, and followed-up for at least 20 years (20-23 years).
  • In comparison with the results reported 17 years ago with a median follow-up of 38 months (range: 27-66), this updated study showed 24 more deaths, 9 more relapses and 3 second malignancies.
  • We conclude that osteosarcoma patients treated with chemotherapy are at risk of late adverse events.
  • Protracted medical follow-up and long-term updated results are useful to identify, at an early stage, late relapses and late treatment-related complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Morbidity. Risk Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15700851.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


63. Billmire D, Vinocur C, Rescorla F, Colombani P, Cushing B, Hawkins E, London WB, Giller R, Lauer S: Malignant mediastinal germ cell tumors: an intergroup study. J Pediatr Surg; 2001 Jan;36(1):18-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This review was conducted to determine clinical characteristics and response to therapy in this rare pediatric neoplasm.
  • METHODS: An intergroup Pediatric Oncology Group (POG) 9049/Children's Cancer Study Group (CCG) 8882 randomized trial was conducted to evaluate response rate and survival with chemotherapy using etoposide, bleomycin, and high or standard dose cisplatin for high-risk malignant germ cell tumors at extragonadal sites.
  • For this review, a secondary analysis of clinical and operative findings in patients with primary site in the mediastinum was carried out.
  • Yolk sac tumor was the only malignant element in girls.
  • Boys had yolk sac tumor in 7, germinoma in 3, choriocarcinoma in 2, and mixed malignant elements in 15.
  • Four patients had biopsy and chemotherapy without tumor resection, and only 1 survived.
  • Fourteen patients had resection at diagnosis followed by chemotherapy with 12 survivors.
  • Eighteen patients had biopsy followed by chemotherapy and postchemotherapy tumor resection with 13 survivors.
  • Tumor size in response to chemotherapy for these 18 patients was stable or increased in 6, and decreased in 12 (mean decrease of 57% in greatest dimension).
  • Ten patients died: 5 of tumor (all boys > or =15 yr), 2 of sepsis, and 3 of second malignancy.
  • CONCLUSIONS: Malignant MGCT is a complex tumor of varied histology with frequent coexistence of benign elements.
  • Lesions often have incomplete regression with chemotherapy alone.
  • Tumor resection may be undertaken at diagnosis or after attempted shrinkage with chemotherapy.
  • Aggressive attempt at complete tumor resection should be offered to all patients even if bulky tumor persists after induction chemotherapy with expectation of a significant salvage rate.
  • Boys > or =15 years may be a high-risk subgroup for mortality from tumor progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mediastinal Neoplasms / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy
  • [MeSH-minor] Adolescent. Biopsy. Bleomycin / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Infant, Newborn. Male. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11150432.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


64. Aziz TA, Aziz MA, Fouad HH, Rashed LA, Salama H, Abd-Alla S, Wehab MA, Ahmed T: Interferon-alpha gene therapy prevents aflatoxin and carbon tetrachloride promoted hepatic carcinogenesis in rats. Int J Mol Med; 2005 Jan;15(1):21-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha gene therapy prevents aflatoxin and carbon tetrachloride promoted hepatic carcinogenesis in rats.
  • To our knowledge, this is the first time an experimental in vivo gene therapy trial was conducted in Egypt.
  • Two genes were examined in liver tissue by RT-PCR: the first was glutathione-S-transferase placental (GST-P) isoenzyme, as an early marker to detect hepatic malignancy; the second was IFN-alpha gene expression to detect the efficiency of gene uptake and its persistence after transduction.
  • Forty male rats, divided equally into 4 groups, were included in the study: the first group was the control; the second group received CCl4 0.2 ml subcutaneously twice weekly for 12 weeks and AFB1 0.25 mg/kg body wt intraperitoneally twice weekly for 6 weeks; the third group received IFN-alpha (10(8) pfu) intravenously in the tail vein prior to the start of CCl4 and AFB1 injections; and the fourth group received IFN-alpha (10(8) pfu) by intrahepatic injection under ultrasonography guide after termination of the CCl4 and AFB1 injection schedule.
  • Pathological examination of liver tissue proved that IFN-alpha minimized both fibrotic and cirrhotic processes.
  • In conclusion, IFN-alpha exerts significant protective effects, but more so when the gene is administered before fibrogenic and carcinogenic induction in hepatic tissues.
  • IFN-alpha gene therapy may be justified in clinical trials for high-risk candidates with hepatic carcinogenesis.
  • [MeSH-major] Aflatoxins / pharmacology. Carbon Tetrachloride / pharmacology. Genetic Therapy. Interferon-alpha / genetics. Interferon-alpha / therapeutic use. Liver Neoplasms, Experimental / genetics. Liver Neoplasms, Experimental / prevention & control
  • [MeSH-minor] Animals. Cell Line. Cell Transformation, Neoplastic / chemically induced. Cell Transformation, Neoplastic / pathology. Disease Models, Animal. Glutathione Transferase / metabolism. Isoenzymes / metabolism. Liver / drug effects. Liver / metabolism. Liver / pathology. Male. Placenta / enzymology. Rats. Transduction, Genetic

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. CARBON TETRACHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583823.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Aflatoxins; 0 / Interferon-alpha; 0 / Isoenzymes; CL2T97X0V0 / Carbon Tetrachloride; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


65. Navarro D, Luzardo OP, Fernández L, Chesa N, Díaz-Chico BN: Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol; 2002 Jul;81(3):191-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostate carcinoma is the most frequently diagnosed malignancy and the second leading cause of death as a result of cancer in men in the western countries.
  • Withdrawal of androgens or the peripheral blockage of androgen action remain the critical therapeutic options for the treatment of advanced prostate cancer.
  • Understanding the mechanisms of transition to androgen independence and tumor progression in prostate cancer is critical to finding new ways to treat aged patients that are ineligible for conventional chemotherapy.
  • Many of these involve the androgen receptor (AR) and its signalling pathways, but they might also include genetic changes that affect several genes, which results in the activation of oncogenes or the inactivation of tumor suppressor genes.
  • [MeSH-major] Androgens / metabolism. Prostatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12163131.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 0 / Receptors, Androgen
  • [Number-of-references] 61
  •  go-up   go-down


66. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol; 2010 Nov 20;28(33):4935-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
  • PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype.
  • PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.
  • Acute nonlymphocytic leukemia risks were significantly elevated after FL and DLBCL, particularly among patients receiving initial chemotherapy, but not after CLL/SLL (SIR: CLL/SLL = 1.13, FL = 5.96, DLBCL = 4.96; P(Diff) < .001).
  • Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).
  • CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk.
  • Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]
  • (PMID = 20940199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3020697
  •  go-up   go-down


67. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M: Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol; 2000 Dec 15;18(24):4016-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To provide an estimate of long-term prognosis for patients with osteosarcoma of the extremity treated in a single institution with neoadjuvant chemotherapy and observed for at least 10 years.
  • Postoperatively, good responders (90% or more tumor necrosis) received the same three drugs used before surgery, whereas poor responders (less than 90% tumor necrosis) received ifosfamide and etoposide in addition to those three drugs.
  • At a follow-up ranging from 10 to 13 years (median, 11.5 years), 101 patients (61%) remained continuously free of disease, 61 relapsed, and two died of ADM-induced cardiotoxicity.
  • ADM-induced cardiotoxicity (six patients), male infertility (10 of the 12 assessable patients), and second malignancies (seven patients) were the major complications of chemotherapy.
  • CONCLUSION: With an aggressive neoadjuvant chemotherapy, it is possible to cure more than 60% of patients with nonmetastatic osteosarcoma of the extremity and amputation may be avoided in more than 80% of them.
  • Because local or systemic relapses, myocardiopathies, and second malignancies are possible even 5 years or more after the beginning of treatment, a long-term follow-up is recommended for these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / surgery. Osteosarcoma / drug therapy. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Cisplatin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Extremities. Female. Fertility / drug effects. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Neoadjuvant Therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / surgery. Patient Compliance. Postoperative Complications / etiology. Postoperative Complications / surgery. Radiography. Reconstructive Surgical Procedures. Reoperation. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11118462.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


68. Wang X, Hershman DL, Abrams JA, Feingold D, Grann VR, Jacobson JS, Neugut AI: Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer; 2007 Dec 17;97(12):1606-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 923 patients with CLM who underwent hepatectomy, 514 were stages I-III and developed CLM>6 months after diagnosis (metachronous), and 409 were stage IV with CLM at diagnosis (synchronous).
  • Both 5-fluorouracil (5FU)-based chemotherapy and hepatic arterial infusion (HAI) of floxuridine-based chemotherapy following hepatectomy improved survival (HR=0.62, 95% CI: 0.50-0.78; HR=0.51, 95% CI: 0.28-0.97, respectively) in the synchronous, but not metachronous, group.
  • The HR for overall mortality was higher in hospitals with a high vs low procedure volume (0.75, 95% CI: 0.58-0.94).
  • High hospital procedure volume and use of 5FU-based or HAI-based chemotherapy after resection were associated with improved prognosis.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1998 May-Jun;45(21):805-11 [9684138.001]
  • [Cites] Hepatogastroenterology. 1995 Apr;42(2):155-61 [7672764.001]
  • [Cites] Ann Surg. 1998 Dec;228(6):756-62 [9860474.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] J Pathol. 2005 Jan;205(2):275-92 [15641020.001]
  • [Cites] N Engl J Med. 2005 Feb 17;352(7):734-5 [15716576.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Abdom Imaging. 2005 Jul-Aug;30(4):419-26 [15759208.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):86-94 [16368496.001]
  • [Cites] Eur J Surg Oncol. 2006 Jun;32(5):557-63 [16580811.001]
  • [Cites] Arch Surg. 2006 Oct;141(10):1006-12; discussion 1013 [17043279.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4976-82 [17075115.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(12):1845-7 [17212124.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):718-26 [17238180.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):243-54 [10637236.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1549-56 [10738212.001]
  • [Cites] Ann Surg. 2000 May;231(5):743-51 [10767796.001]
  • [Cites] JAMA. 2000 Dec 20;284(23):3028-35 [11122590.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] Surgery. 2001 Apr;129(4):408-13 [11283530.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 4;93(7):501-15 [11287444.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1499-505 [11896097.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] J Am Coll Surg. 2002 Aug;195(2):196-202 [12168966.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-19-25 [12187164.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-26-35 [12187165.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-43-8 [12187167.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-55-61 [12187169.001]
  • [Cites] Arch Surg. 2003 Feb;138(2):185-91 [12578418.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):871-83; discussion 883-4 [14631224.001]
  • [Cites] Surg Gynecol Obstet. 1970 Oct;131(4):697-700 [5458530.001]
  • [Cites] Arch Surg. 1976 Apr;111(4):330-4 [1259571.001]
  • [Cites] Am J Surg. 1978 Mar;135(3):389-94 [626320.001]
  • [Cites] J Chronic Dis. 1986;39(6):439-52 [3086355.001]
  • [Cites] Br J Surg. 1990 Nov;77(11):1241-6 [2253003.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] Lancet. 1994 Jun 4;343(8910):1405-10 [7515134.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Curr Probl Surg. 1995 May;32(5):333-421 [7538062.001]
  • [Cites] JAMA. 1998 Nov 25;280(20):1747-51 [9842949.001]
  • (PMID = 18071347.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA095597; United States / NCI NIH HHS / CA / R25 CA094061; United States / NLM NIH HHS / LM / T15 LM007079; United States / NCI NIH HHS / CA / CA94061
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2360280
  •  go-up   go-down


69. Vergnon JM: [Supportive care. Endoscopic treatments for lung cancer]. Rev Mal Respir; 2008 Oct;25(8 Pt 2):3S160-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Supportive care. Endoscopic treatments for lung cancer].
  • In the first situation, the goal is palliative and the treatment is based on a mechanical debulking with a rigid bronchoscope to core out the tumour and/or to insert stent in cases of external compression.
  • Interventional bronchoscopy is mandatory before chemotherapy or radiotherapy in patients either with a symptomatic airway obstruction or with an obstruction more than 50% of the lumen of a major bronchus.
  • In some cases, a synergic action between therapeutic bronchoscopy and conventional radio-chemotherapy is observed.
  • In early stages (superficial lung cancers) the treatment can be curative with methods sparing the bronchial wall, such as cryotherapy, electrocautery in soft mode, photodynamic therapy or brachytherapy.
  • In these superficial lesions, synchronous tumours are frequent and 5% per year of metachronous lesions are observed in the follow-up.
  • Thus, sparing lung parenchyma can be crucial and explains the growing role of therapeutic bronchoscopy as alternative to surgery.
  • [MeSH-major] Bronchoscopy. Lung Neoplasms / therapy
  • [MeSH-minor] Airway Obstruction / etiology. Airway Obstruction / therapy. Algorithms. Humans

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18971841.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


70. Benazzo M, Caracciolo G, Zappoli F, Bernardo G, Mira E: Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer. Eur Arch Otorhinolaryngol; 2000;257(5):279-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer.
  • To evaluate the feasibility, maximum dose of drug tolerated, technical problems, systemic and local toxicity, response rate, overall and disease-free survival, we studied superselective intra-arterial infusion of high-dose carboplatin as part of a multimodality treatment for head and neck cancer.
  • Forty patients with untreated stage II-IV head and neck squamous cell carcinomas received induction chemotherapy with high-dose carboplatin (three cycles at 2-week intervals using 300-350 mg/m2 per cycle), delivered via superselective transfemoral angiography followed by radiotherapy or surgery plus radiotherapy.
  • At the end of chemotherapy the overall complete and partial response rate was 90% (36/40) at the primary site and 64% (16/25) at the neck nodes.
  • To date 21 patients are alive without disease, 2 are alive with disease, 13 have died of disease, and 4 have developed a metachronous lung tumor.
  • There was a good correlation between the response to chemotherapy and disease-free survival.
  • However, discriminating between responding and nonresponding patients, this procedure can have a prognostic significance in planning integrated treatments for these types of tumors.
  • [MeSH-major] Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Infusions, Intra-Arterial. Otorhinolaryngologic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusion Pumps. Male. Middle Aged. Neoplasm Staging

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10923944.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  •  go-up   go-down


71. Moehler M, Lyros O, Gockel I, Galle PR, Lang H: Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol; 2008 Jun 28;14(24):3773-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinomas of the stomach and gastroesophageal junction are among the five top leading cancer types worldwide.
  • In spite of radical surgical R0 resections being the basis of cure of gastric cancer, surgery alone provides long-term survival in only 30% of patients with advanced International Union Against Cancer (UICC) stages in Western countries because of the high risk of recurrence and metachronous metastases.
  • However, recent large phase-III studies improved the diagnostic and therapeutic options in gastric cancers, indicating a more multidisciplinary management of the disease.
  • In particular, the perioperative (neoadjuvant, adjuvant) chemotherapy is now a well-established new standard of care for advanced tumors.
  • Adjuvant therapy alone should be carefully discussed after surgical resection, mainly in individual patients with large lymph node positive tumors when neoadjuvant therapy could not be done.
  • The palliative treatment options have also been remarkably improved with new chemotherapeutic agents and will further be enhanced with targeted therapies such as different monoclonal antibodies.
  • [MeSH-major] Esophageal Neoplasms / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Esophagogastric Junction / drug effects. Esophagogastric Junction / surgery. Humans. Neoadjuvant Therapy. Palliative Care

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2431-8 [9815644.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 6:vi13-8 [16809641.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1522-30 [10188901.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):170-8 [10450730.001]
  • [Cites] Eur J Cancer. 1999 Apr;35(4):558-62 [10492627.001]
  • [Cites] Dig Dis. 2004;22(4):345-50 [15812158.001]
  • [Cites] Eur J Med Res. 2005 Feb 28;10(2):88-91 [15817429.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2122-8 [15942629.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4509-17 [16002841.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):663-7 [16446338.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Apr;4(4):350-66 [16569388.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2903-9 [16782930.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3953-8 [16921048.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] Ann Surg Oncol. 2007 Jul;14(7):2010-7 [17342569.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1354-8 [17525087.001]
  • [Cites] Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):121-30 [10550836.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Endoscopy. 2002 Jan;34(1):21-8 [11778127.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] J Clin Gastroenterol. 2002 Oct;35(4):321-7 [12352295.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):828-35; discussion 835-7 [12796579.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii45-7 [12810458.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1373-7 [12954575.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23 Suppl):274s-275s [14645409.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] Onkologie. 2003 Dec;26 Suppl 7:54-9 [14716144.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):658-63 [14966088.001]
  • [Cites] J Surg Oncol. 2004 Mar 15;85(4):181-5; discussion 186 [14991872.001]
  • [Cites] Br J Surg. 2004 May;91(5):540-51 [15122603.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2767-73 [15199090.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2774-80 [15254045.001]
  • [Cites] Surg Endosc. 2004 Jul;18(7):1067-70 [15156385.001]
  • [Cites] Lancet. 1994 May 28;343(8909):1309-12 [7910321.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Curr Opin Oncol. 1996 Jul;8(4):321-8 [8869808.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] Gut. 2007 Nov;56(11):1625-34 [17938435.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(2):182-94 [18093827.001]
  • [Cites] Ann Oncol. 2008 Aug;19(8):1450-7 [18558665.001]
  • [Cites] Ann Surg Oncol. 2012 Jan;19(1):68-74 [21879261.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • (PMID = 18609699.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] China
  • [Number-of-references] 59
  • [Other-IDs] NLM/ PMC2721432
  •  go-up   go-down


72. Miura H, Nakajima N, Takahashi H, Kinoshita M, Ikeda N: [Therapeutic strategy for secondary lung cancer]. Kyobu Geka; 2010 Oct;63(11):956-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic strategy for secondary lung cancer].
  • The secondary tumors were synchronous, located in the same lobe in 10, the ipsilateral different lobe in 17, and the contralateral lobe in 13, or metachronous, located in the contralateral lobe in 15, and the ipsilateral different lobe in 5.
  • Chemotherapy, stereotactic radiotherapy (SRT), photo dynamic therapy (PDT), or best supportive care (BSC) was selected after a lobectomy or segmentectomy of the 1st tumor in 8 cases considering the patient's condition.
  • Lobectomy or segmentectomy should be indicated for the 1st tumor considering curability.
  • Considering the patient's condition, possibility of metastases and the tumor location and histologic type, partial resection, SRT, PDT, or BSC could be selected.
  • [MeSH-major] Lung Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Neoplasms, Second Primary / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20954350.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


73. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V: An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia; 2004 Sep;18(9):1476-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
  • In addition, the probability of obtaining another response with this drug in pts who relapsed after 2-CdA treatment will be addressed.
  • A total of 44 consecutive pts (34 males, 10 females) with a median age of 57 years (range 33-77) at the time of initiation of 2-CdA treatment were analyzed.
  • The median time to the start of 2-CdA treatment of the 11 pretreated pts was 47 months (mo) (10-160).
  • Out of 44, 43 (98%) achieved complete response (CR) (13 pts with residual disease-RD), one pt reached a good partial response with a single cycle of 2-CdA.
  • Bone marrow biopsies were performed at the time of recovery of hematopoiesis, thereafter at 2-3 mo intervals, thereafter at 6 mo, and finally annually in 35 pts.
  • Disease-free survival from the start of 2-CdA treatment is 36% at 12 years (median 8.4 years), 17/44 pts relapsed.
  • Nine of these pts were treated with 2-CdA again, eight achieved a second CR (median 2.5 yrs), one pt did not respond.
  • Eight of our cohort had a second malignancy before receiving 2-CdA.
  • Six pts died in CR due to the second malignancy.
  • The overall survival at 12 years after the start of 2-CdA treatment is 79%.
  • 2-CdA is a safe and effective treatment of HCL inducing complete remissions in the majority of pts with only a single cycle of 2-CdA, and a paucity of toxicities.
  • Pts who relapsed following treatment with 2-CdA responded to subsequent retreatment with 2-CdA.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cladribine / therapeutic use. Leukemia, Hairy Cell / drug therapy. Neoplasm, Residual / drug therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Follow-Up Studies. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / surgery. Palliative Care. Pentostatin / administration & dosage. Pentostatin / therapeutic use. Splenectomy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15229616.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 395575MZO7 / Pentostatin; 47M74X9YT5 / Cladribine
  •  go-up   go-down


74. Hartmann JT, Rick O, Oechsle K, Kuczyk M, Gauler T, Schöffski P, Schleicher J, Mayer F, Teichmann R, Kanz L, Bokemeyer C: Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors. Ann Surg; 2005 Aug;242(2):260-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Forty-three male patients with nonseminoma were treated in different multicenter treatment protocols between 1990 and 1999, and they underwent hepatic surgery.
  • RESULTS: Thirty-five of 43 patients (81%) were initially diagnosed with liver metastases and advanced GCT, and 8 patients (19%) presented with metachronous liver metastases after a median interval of 16 months (range, 6-103 months).
  • Twelve patients (28%) had isolated liver metastases after completion of chemotherapy, while 31 patients (72%) had additional residual extrahepatic tumor masses.
  • Liver surgery included tumor excision or segmentectomy in 32 patients (74%) and hepatectomy (right/left) or resection of multiple segments in 11 patients (26%).
  • Refractoriness to chemotherapy was associated with a shorter survival after surgery, and a trend was seen in patients with elevation of AFP.
  • CONCLUSION: The high rate of viable cancer and teratoma found in liver specimens, differing histologic results at residual tumor locations, and the high survival rate achieved support a multidisciplinary approach including resection of liver masses since no accurate selection of patients can narrow the use of surgery.
  • [MeSH-major] Germinoma / secondary. Germinoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Hepatectomy. Humans. Male. Middle Aged. Neoplasm, Residual / pathology. Teratoma / drug therapy. Teratoma / mortality. Teratoma / secondary. Teratoma / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):640-4 [10560848.001]
  • [Cites] N Engl J Med. 1997 Jul 24;337(4):242-53 [9227931.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):578-87 [11505402.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1017-28 [12176779.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3310-7 [12947067.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4083-91 [14568987.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1377-99 [15319245.001]
  • [Cites] Ann Thorac Surg. 1983 Nov;36(5):524-8 [6195980.001]
  • [Cites] Br J Cancer. 1984 Nov;50(5):601-9 [6093838.001]
  • [Cites] Cancer. 1986 Mar 1;57(5):978-83 [3002596.001]
  • [Cites] Cancer. 1989 Feb 1;63(3):440-5 [2912523.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1683-94 [2170590.001]
  • [Cites] J Urol. 1991 Feb;145(2):300-2; discussion 302-3 [1988722.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1329-34 [8055456.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):960-5 [7524606.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1177-87 [7537801.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1765-9 [8656244.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):531-8 [9261521.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):843-7 [9291803.001]
  • [Cites] Br J Urol. 1997 Oct;80(4):653-7 [9352708.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):81-8 [11134198.001]
  • (PMID = 16041217.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1357732
  •  go-up   go-down


75. Sarini J, Fournier C, Lefebvre JL, Bonafos G, Van JT, Coche-Dequéant B: Head and neck squamous cell carcinoma in elderly patients: a long-term retrospective review of 273 cases. Arch Otolaryngol Head Neck Surg; 2001 Sep;127(9):1089-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prolongation of life expectancy results in an increasing number of malignant neoplasms occurring in the elderly population.
  • For a long time these patients were not considered good candidates to receive aggressive therapy and probably were inadequately treated in many instances.
  • There were no differences for primary site except for hypopharyngeal squamous cell carcinoma that occurred less frequently in the elderly patients (8.8% vs 14.5%, borderline significance P =.02).
  • Surgery was performed in a smaller proportion of older patients (13.9% vs 27.4%, P<.001, for the primary site and 15.4% vs 35.6%, P<.001, for those occurring in the neck) as well as chemotherapy that was delivered in 5.5% vs 17.7% (P<.001).
  • On the contrary, there was no difference in radiotherapeutic treatments.
  • Tolerance to treatment was similar and there was the same proportion of persistent diseases 2 months after completion of the overall treatment (27.8% vs 25.4%, P =.94).
  • Pooling local, regional, and distant failures and metachronous cancers, there was a borderline lower incidence in older patients (57.1% vs 64.2%, P =.02), which is explained by an obvious shorter life expectancy.
  • Among the 4067 patients who were dead at the last update, index tumor evolution-related deaths numbered 130 (48.1% of dead patients in this cohort) in older patients compared with 2045 (53.9% of dead patients in this cohort), which was not significantly different.
  • There was no difference in treatment-related deaths (11.1% vs 9.3%).
  • Fewer intercurrent disease-related deaths occurred in the older patients (19.7% vs 11.8%).
  • When properly monitored, conventional therapies seem feasible in older patients.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11556858.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Bockhorn M, Frilling A, Frühauf NR, Neuhaus J, Molmenti E, Trarbach T, Malagó M, Lang H, Broelsch CE: Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference? J Gastrointest Surg; 2008 Aug;12(8):1399-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference?
  • BACKGROUND: The aim of this study was to compare outcomes in patients with synchronous and metachronous colorectal liver metastases, with special emphasis on prognostic determinants.
  • STUDY DESIGN: We analyzed prospectively collected data on 101 patients with synchronous metastases (group A) who were treated surgically during the time period from April 1998 to December 2006 in regard to overall and disease-free survival, impact of chemotherapy, as well as several serum parameters.
  • A group of patients with metachronous colorectal liver metastases (group B) was considered for baseline comparison.
  • Surgical treatment included right hepatectomy (n = 7), left hepatectomy (n = 5), right trisectionectomy (n = 10), left trisectionectomy (n = 1), left lateral resection (n = 11), and sectionectomy (n = 44).
  • The corresponding rates for metachronous metastases were 94%, 68%, and 39% (p > 0.05).
  • Disease free survival was 74%, 42%, and 33% in group A versus 84%, 62%, and 13% in group B (p = 0.28).
  • There was no difference in survival between patients receiving neoadjuvant chemotherapy and no chemotherapy (p > 0.05).
  • Out of all serum parameters, carcinoembryonic antigen levels were a negative predictor for overall and disease-free survival only.
  • CONCLUSIONS: Patients with synchronous colorectal liver metastases had a similar 5-year overall and disease-free survival, which corresponds to patients with metachronous metastases.
  • The impact of neoadjuvant chemotherapy in patients with synchronous metastases needs to be further clarified.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Germany / epidemiology. Hepatectomy / methods. Humans. Laparotomy. Male. Middle Aged. Prognosis. Prospective Studies. Survival Rate / trends

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Mar;15(3):938-46 [9060531.001]
  • [Cites] Br J Surg. 1990 Nov;77(11):1241-6 [2253003.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Eur J Ultrasound. 2003 Feb;16(3):211-6 [12573790.001]
  • [Cites] Am J Surg. 2005 Jul;190(1):75-86 [15972177.001]
  • [Cites] J Vasc Interv Radiol. 2005 Jun;16(6):779-90 [15947041.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(2):79-83 [15127268.001]
  • [Cites] Lancet. 2003 Jun 7;361(9373):1959 [12801743.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):374-80 [15915371.001]
  • [Cites] Surgery. 1994 Oct;116(4):703-10; discussion 710-1 [7940169.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Baillieres Best Pract Res Clin Gastroenterol. 1999 Dec;13(4):557-74 [10654920.001]
  • [Cites] Surgery. 2004 Sep;136(3):650-9 [15349115.001]
  • [Cites] Br J Surg. 2007 Sep;94(9):1133-8 [17514637.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1032-5 [8402060.001]
  • [Cites] Colorectal Dis. 2003 Jan;5(1):2-23 [12780921.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii144-9 [15958446.001]
  • [Cites] ANZ J Surg. 2002 Jan;72(1):2 [11906413.001]
  • [Cites] World J Surg. 1991 Jan-Feb;15(1):62-7 [1994607.001]
  • [Cites] Arch Surg. 2005 Jul;140(7):629-38; discussion 638 [16027326.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Ann Surg. 2000 May;231(5):743-51 [10767796.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):956-62 [12905548.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(5):607-13 [12541048.001]
  • [Cites] Am J Surg. 1995 Feb;169(2):254-60 [7840389.001]
  • [Cites] Br J Surg. 2004 Mar;91(3):327-33 [14991634.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8490-9 [16230676.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):193-200 [12532430.001]
  • [Cites] Ann Oncol. 2004;15 Suppl 4:iv43-53 [15477334.001]
  • [Cites] J Gastrointest Surg. 2006 Feb;10(2):240-8 [16455457.001]
  • [Cites] Int J Clin Oncol. 2005 Apr;10(2):97-102 [15864694.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • (PMID = 18521698.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Ueda A, Yoshidome H, Kagawa S, Kimura F, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Suda K, Takano S, Kuboki S, Miyazaki M: [Two-stage hepatectomy combined with converting chemotherapy achieved a successful treatment for initially unresectable multiple bilobar colorectal liver metastases]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2557-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two-stage hepatectomy combined with converting chemotherapy achieved a successful treatment for initially unresectable multiple bilobar colorectal liver metastases].
  • A 60-year-old man having metachronous multiple bilobar colorectal liver metastases was referred to our institution.
  • He underwent 13 courses of mFOLFOX6 + bevacizumab as down-staging chemotherapy.
  • After the rest of chemotherapy for 4 weeks, four tumors were resected and right branch of the portal vein embolization was performed at the first operation.
  • He has no signs of tumor recurrence during the follow-up.
  • The combination of two-stage hepatectomy and neoadjuvant systemic chemotherapy may contribute to improve prognoses of initially unresectable multiple bilobar colorectal liver metastases, leading to prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / therapy
  • [MeSH-minor] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bevacizumab. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Organoplatinum Compounds / administration & dosage

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224638.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


78. Sasaki S, Ishimaru M, Suzuki H, Ogawa M, Sato Y: [Significance of CEA to predict the effect of chemotherapy with bevacizumab]. Gan To Kagaku Ryoho; 2010 Mar;37(3):463-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of CEA to predict the effect of chemotherapy with bevacizumab].
  • PURPOSE: Since chemotherapy with bevacizumab has become available for advanced colorectal cancer, its effectiveness has been reported.
  • The purpose of this study was to evaluate the significance of CEA to predict the effect of chemotherapy with bevacizumab.
  • SUBJECTS AND METHODS: Twenty-five patients with advanced colorectal cancer were given chemotherapy with bevacizumab since August 2007.
  • Chemotherapy with bevacizumab was given for 7 cases with metachronous recurrences after curative operations (6 cases with liver and/or lung metastasis and 1 case with pelvic recurrence), and for 11 cases with synchronous liver and/or lung metastasis.
  • First-line chemotherapy was given to 16 cases and second-line to 2 cases.
  • The response rate in 3 cases whose CEA was within the normal range before chemotherapy was 100%.
  • CONCLUSION: In chemotherapy with bevacizumab, the response rate in patients with normal CEA was higher than that in patients with high CEA.
  • Patients with a CEA level of 100 ng/mL or more had a short CEA-controlled period, suggesting the effect of chemotherapy was small in those patients.
  • There is a possibility that CEA might be clinically useful as a biomarker to predict treatment efficacy in chemotherapy with bevacizumab.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Biomarkers / analysis. Carcinoembryonic Antigen / analysis. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332684.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers; 0 / Carcinoembryonic Antigen; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


79. Senkus E, Konefka T, Nowaczyk M, Jassem J: Second lower genital tract squamous cell carcinoma following cervical cancer. A clinical study of 46 patients. Acta Obstet Gynecol Scand; 2000 Sep;79(9):765-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second lower genital tract squamous cell carcinoma following cervical cancer. A clinical study of 46 patients.
  • BACKGROUND: Patients after treatment for cervical cancer have increased risk of developing second squamous cell malignancy of the lower genital tract.
  • MATERIAL AND METHODS: A retrospective study of 46 patients with second lower genital tract epidermoid cancers following previous treatment for invasive cervical carcinoma.
  • RESULTS: Patient age at diagnosis of cervical cancer was 27 to 68 years (median 44 years) and at diagnosis of the second malignancy - 43 to 72 years (median 63 years).
  • Time span between metachronous malignancies ranged from 66 to 406 months (median 206 months).
  • In 32 cases (70%) second lesion was located in the vagina and in 14 (30%) - in the vulva.
  • Out of 35 previously irradiated patients, in 24 (69%) second tumor was located within the high dose volume and in 11 (31%) - outside it.
  • Treatment of second cancer consisted of surgery in 12 patients (26%), radiotherapy in 23 (50%), combined surgery and radiotherapy--in five (11%), chemotherapy in four (9%) and surgery plus chemotherapy - in one case.
  • Median survival was 52 months and five-year survival from the diagnosis of second malignancy - 47.5%.
  • CONCLUSION: Treatment outcome in patients with second lower genital tract carcinoma is unsatisfactory due to poor feasibility of another definite treatment after previous radical surgery and/or radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Uterine Cervical Neoplasms / pathology. Vaginal Neoplasms / mortality. Vulvar Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Palliative Care. Poland / epidemiology. Retrospective Studies. Survival Analysis. Treatment Outcome


80. Liu JH, Hsieh YY, Chen WS, Hsu YN, Chau GY, Teng HW, King KL, Lin TC, Tzeng CH, Lin JK: Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases. Int J Colorectal Dis; 2010 Oct;25(10):1243-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
  • PURPOSE: Adjuvant systemic 5-fluorouracil (5-FU)-based chemotherapy improves survival after resection of synchronous colorectal liver metastases (CLMs), but not metachronous.
  • We retrospectively examined if adjuvant chemotherapy with new regimen containing oxaliplatin or irinotecan improved survivals after resection of metachronous CLMs.
  • METHODS: Between 2000 and 2007, 52 patients having undertaken resection of metachronous CLMs with curative intent were identified from Taipei Veterans General Hospital hospitalization registry.
  • Thirty-one patients experienced six to 12 cycles of FOLFOX or FOLFIRI chemotherapy while 19 patients with 5-FU/leucovorin (LV)-based chemotherapy following CLM resection.
  • The primary end point was disease-free survival (DFS) and secondary end point, overall survival (OS).
  • FOLFOX/FOLFIRI chemotherapy was shown by multivariate analyses to be an independent factor predicting a better DFS (hazard ratio [HR] = 0.37; 95% CI: 0.15-0.94; P = 0.036) and a better OS (HR = 0.27; 95% CI: 0.083-0.86, P = 0.026) than 5-FU/LV-based.
  • CONCLUSIONS: Adjuvant FOLFOX/FOLFIRI chemotherapy following resection of metachronous CLMs is demonstrated to have better DFS and OS than 5-FU/LV chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Colorectal Neoplasms / drug therapy. Liver Neoplasms / secondary. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Aged. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3109-16 [19451431.001]
  • [Cites] Int J Colorectal Dis. 2009 Apr;24(4):419-25 [19096855.001]
  • [Cites] Cancer Treat Rev. 2009 Dec;35(8):668-75 [19733977.001]
  • [Cites] J Surg Oncol. 2009 Dec 15;100(8):713-8 [19771561.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):853-8 [20048179.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2039-48 [10615075.001]
  • [Cites] Eur J Cancer. 1999 Sep;35(9):1343-7 [10658525.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Surgery. 2001 Apr;129(4):408-13 [11283530.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1499-505 [11896097.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Br J Cancer. 2002 Aug 12;87(4):393-9 [12177775.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):871-83; discussion 883-4 [14631224.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] Lancet. 1994 Jun 4;343(8910):1405-10 [7515134.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):808-15 [9053508.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4553-60 [16002847.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4976-82 [17075115.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12):1606-12 [18071347.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4906-11 [18794541.001]
  • [Cites] Int J Colorectal Dis. 2009 Jan;24(1):83-6 [18766356.001]
  • [Cites] J Surg Oncol. 2009 Oct 1;100(5):349-57 [19572329.001]
  • (PMID = 20574727.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; Folfox protocol
  • [Other-IDs] NLM/ PMC2928445
  •  go-up   go-down


81. Mori N, Sawada T, Satoh H, Kawaguchi M, Hara H, Matsushita K: A resected case of solitary pancreatic metastasis from adenocarcinoma of the lung. JOP; 2008;9(6):698-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Primary lung cancer frequently metastasizes to distant organs; however, the pancreas is a relatively infrequent site of metastasis.
  • Because most metastatic cases in the pancreas tend to be discovered in patients only after malignant disease has become widely disseminated, it is extremely rare that a metachronous metastatic lesion limited to the pancreas is discovered with postoperative imaging and is surgically resectable.
  • Although several cases have been reported of patients who underwent pancreatic resection for curative intent, most patients died from recurrent disease.
  • CASE REPORT: We report herein an unusual case of secondary tumor of the pancreas (primary tumor: adenocarcinoma of the lung) with hopefully curative resection.
  • The interval between the surgical treatment of lung cancer and the metachronous pancreatic metastasis was 22 months; there has been no recurrence of disease during the 24 months of follow-up after a pylorus-preserving pancreaticoduodenectomy.
  • CONCLUSION: Surgical treatment should be considered in patients with pancreatic metastasis from other organs if the disease is localized in the pancreas or if metastasis in other organs is controlled with chemotherapy and/or radiotherapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Back Pain / etiology. Humans. Male. Middle Aged. Neoplasm Metastasis. Recurrence. Shoulder Pain / etiology. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


82. Guastafierro S, Falcone U, Celentano M, Ferraraccio F, Iovino F: Primary non-Hodgkin lymphoma of the breast as third malignancy in one patient. Am J Med Sci; 2008 Nov;336(5):434-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin lymphoma of the breast as third malignancy in one patient.
  • We report a case of primary non-Hodgkin lymphoma of the breast as third metachronous neoplasm in the same patient.
  • Primary non-Hodgkin lymphoma of the breast occurred about 2 years after endometrial cancer and 1 year after bladder cancer.
  • The patient underwent quadrantectomy with level I-II axillary lymph nodes dissection plus rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Aged. Endometrial Neoplasms / pathology. Fatal Outcome. Female. Humans. Urinary Bladder Neoplasms / pathology


83. Mateş IN, Dinu D, Iosif C, Anghelescu L, Constantinoiu S: [Simultaneous bilateral breast carcinoma--case study and review of primitive bilateral breast cancer]. Chirurgia (Bucur); 2007 Jul-Aug;102(4):471-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Simultaneous bilateral breast carcinoma--case study and review of primitive bilateral breast cancer].
  • Bilateral breast cancer is uncommon and difficult to define because it may manifest as simultaneous, synchronous or metachronous tumours.
  • Three sessions of chemotherapy were followed by simultaneous left Madden mastectomy and right simple mastectomy (frozen sections negative for malignancy).
  • Based on clinical, epidemiologic, morphologic and genetic evidence, bilateral breast cancers (synchronous or metachronous) are considered to be a special evolutive entity of breast cancer.
  • Our case suggests that, in the absence of risk factors for bilaterality of breast carcinoma: description of bilateral breast cancers based on diagnostic chronology of the two tumours is arbitrary; they may occur sporadically and have independent evolution; their biology rather resembles a multiple primitive malignancy than a true bilateral breast cancer.
  • [MeSH-major] Breast Neoplasms. Carcinoma. Mastectomy. Neoplasms, Multiple Primary
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966947.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 58
  •  go-up   go-down


84. Rice SC, Vacek P, Homans AH, Messier T, Rivers J, Kendall H, Finette BA: Genotoxicity of therapeutic intervention in children with acute lymphocytic leukemia. Cancer Res; 2004 Jul 1;64(13):4464-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotoxicity of therapeutic intervention in children with acute lymphocytic leukemia.
  • The survival rates of children treated for cancer have dramatically increased after the development of standardized multiple-modality treatment protocols.
  • To study the genotoxic effects of antineoplastic treatment in children, we performed a comparative analysis of the changes in the frequency of somatic mutations (Mfs) at the hypoxanthine-guanine phosphoribosyltransferase (HPRT)-reporter gene in children treated for acute lymphocytic leukemia (ALL).
  • We measured HPRT Mfs from 130 peripheral blood samples from 45 children with ALL (13, low risk; 22, standard risk; and 10, high risk) from the time of diagnosis, as well as during and after the completion of therapy.
  • We observed a significant increase in mean HPRT Mfs during each phase of therapy (diagnosis, 1.4 x 10(-6); consolidation, 52.1 x 10(-6); maintenance, 93.2 x 10(-6); and off-therapy, 271.7 x 10(-6)) that were independent of the risk group treatment protocol used.
  • This 200-fold increase in mean somatic Mf remained elevated years after the completion of therapy.
  • We did not observe a significant difference in the genotoxicity of each risk group treatment modality despite differences in the compositional and clinical toxicity associated with these treatment protocols.
  • These findings suggest that combination chemotherapy used to treat children with ALL is quite genotoxic, resulting in an increased somatic mutational load that may result in an elevated risk for the development of multi-factorial diseases, in particular second malignancies.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15231655.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 P20RR16462; United States / NCI NIH HHS / CA / 1K01CA77737; United States / NCI NIH HHS / CA / 1R01CA09094013; United States / NICHD NIH HHS / HD / 1R29HD35309; United States / NCI NIH HHS / CA / P30CA22435
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.4.2.8 / Hypoxanthine Phosphoribosyltransferase
  •  go-up   go-down


85. Gambassi G, Semeraro R, Suma V, Sebastio A, Incalzi RA: Aggressive behavior of classical Kaposi's sarcoma and coexistence with angiosarcoma. J Gerontol A Biol Sci Med Sci; 2005 Apr;60(4):520-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology allowed a diagnosis of the classical form of Kaposi's sarcoma; the serology test result for HIV was negative, whereas the associated human herpes virus type 8 was detected by polymerase chain reaction on the skin sample.
  • Chemotherapy with vinblastine appeared to stabilize the cutaneous disease, but the patient developed a massive gastrointestinal hemorrhage secondary to dissemination to the stomach.
  • Twelve months after the onset of the disease, vegetative and easily bleeding lesions progressively occluded the mouth of the patient: histological features were consistent with a low-grade angiosarcoma distinct from that of Kaposi's sarcoma.
  • This case illustrates that, even in its classical form, Kaposi's sarcoma may be a malignant, rapidly progressing tumor.
  • LEARNING POINTS: a) The extent and rate of spread of initial skin lesions should be considered to be early signs of aggressive dissemination, even in the absence of other variables (i.e., histological pattern, human herpes virus type 8 positive mononuclear cells) associated with progression of the disease.
  • c) When classical Kaposi's sarcoma displays aggressive behavior a second, primary malignant tumor arising from the vascular tissue should be investigated.
  • TAKE-HOME MESSAGE: Even in its classical form, Kaposi's sarcoma may be a malignant, rapidly progressing tumor with visceral involvement; also, a second malignancy may occur in nearly one patient of four.
  • [MeSH-major] Foot Diseases / pathology. Hemangiosarcoma / pathology. Neoplasms, Multiple Primary / pathology. Palatal Neoplasms / pathology. Sarcoma, Kaposi / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Fatal Outcome. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933395.001).
  • [ISSN] 1079-5006
  • [Journal-full-title] The journals of gerontology. Series A, Biological sciences and medical sciences
  • [ISO-abbreviation] J. Gerontol. A Biol. Sci. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Bokemeyer C, Hartmann JT, Fossa SD, Droz JP, Schmol HJ, Horwich A, Gerl A, Beyer J, Pont J, Kanz L, Nichols CR, Einhorn L: Extragonadal germ cell tumors: relation to testicular neoplasia and management options. APMIS; 2003 Jan;111(1):49-59; discussion 59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extragonadal germ cell tumors: relation to testicular neoplasia and management options.
  • An unselected population of 635 consecutive extragonadal GCT patients (EGCT) treated between 1975 through 1996 at 11 cancer centers was retrospectively evaluated for clinical prognosis and biological features of this disease.
  • Five hundred twenty-four patients (83%) had a nonseminomatous GCT, and 104 patients (16%) a seminomatous histology; 341 (54%) patients had a primary mediastinal EGCT, and 283 patients (45%) a retroperitoneal EGCT.
  • Following platinum based induction chemotherapy+/-secondary surgery, 141 patients (49%) with mediastinal nonseminomas (median follow up period: 19 months) and 144 patients (63%) with retroperitoneal nonseminoma (median follow up period: 29 months) are alive [p=0.0006].
  • In contrast, the overall survival rate for patients with seminomatous EGCT is 88% with no difference between patients with mediastinal or retroperitoneal tumor location (median follow up period: 49 months).
  • Multivariate analysis revealed nonseminomatous histology, the presence of non-pulmonary visceral metastases, primary mediastinal GCT location, and elevated beta-HCG as independent prognostic factors for shorter survival.
  • Sixteen patients (4.1%) developed a metachronous testicular cancer despite the use of platinum based chemotherapy.
  • After a median follow-up of 51 months (range=1 to 154 months), all 16 MTC patients were alive without disease.
  • Patients with pure seminomatous EGCT histology have a long term chance of cure of almost 90% irrespective of the primary tumor site.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Germinoma / secondary. Germinoma / therapy. Mediastinal Neoplasms / therapy. Neoplasms, Second Primary / therapy. Retroperitoneal Neoplasms / therapy. Testicular Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers / analysis. Chorionic Gonadotropin, beta Subunit, Human / analysis. Cisplatin / therapeutic use. Drug Therapy, Combination. Hematologic Diseases / pathology. Humans. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Seminoma / pathology. Seminoma / therapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12752235.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Chorionic Gonadotropin, beta Subunit, Human; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


87. Kies MS, Bennett CL, Vokes EE: Locally advanced head and neck cancer. Curr Treat Options Oncol; 2001 Feb;2(1):7-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The simultaneous administration of chemotherapy and radiation has produced a significant impact on the treatment of advanced squamous cell carcinomas of the head and neck.
  • Although no single regimen has emerged as the "standard" approach, recent trials have consistently demonstrated the superiority of combined treatment programs over radiotherapy alone for local tumor control and overall survival.
  • Moreover, multimodal treatment has emerged with important ancillary goals of organ preservation, improved cosmesis, and enhancement of quality of life.
  • With improving survival in all stages of disease, much attention can be given to identifying effective measures to reduce the risk of metachronous primary cancers in this high-risk group.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Forecasting. Humans. Neoplasm Invasiveness. Neoplasm Recurrence, Local / prevention & control. Quality of Life. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] AJR Am J Roentgenol. 1976 Feb;126(2):229-35 [175693.001]
  • [Cites] Clin Radiol. 1980 Sep;31(5):617-20 [6162599.001]
  • [Cites] Clin Radiol. 1987 Nov;38(6):575-81 [3121233.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1242-5 [4027864.001]
  • [Cites] JAMA. 1996 Oct 16;276(15):1253-8 [8849754.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2648-53 [7989940.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2715-21 [9704722.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1318-24 [9552032.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):21-8 [1993628.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1652-61 [10764425.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5113-20 [8221647.001]
  • [Cites] Semin Oncol. 1993 Feb;20(1):70-9 [8475412.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):184-94 [8417385.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):429-35 [7619114.001]
  • [Cites] J Clin Oncol. 1987 Sep;5(9):1410-8 [2442323.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):268-76 [8996152.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):876-83 [7707114.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):999-1004 [8985019.001]
  • (PMID = 12057136.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 25
  •  go-up   go-down


88. Shvidel L, Sigler E, Shtalrid M, Feldberg E, Berrebi A: Parotid gland involvement, the presenting sign of high grade non-Hodgkin lymphoma in two patients with Gaucher disease and sicca syndrome. J Inherit Metab Dis; 2007 Oct;30(5):825
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid gland involvement, the presenting sign of high grade non-Hodgkin lymphoma in two patients with Gaucher disease and sicca syndrome.
  • Increased risk of haematological malignancies has been described in Gaucher disease patients; however, high-grade lymphoma has been rarely observed.
  • We report two patients with Gaucher disease and sicca syndrome diagnosed with aggressive lymphoma involving the parotid gland.
  • A 29-year-old woman with Gaucher disease developed tumour of the left parotid gland.
  • Bone biopsy revealed focal lymphomatous infiltration consistent with stage IV disease.
  • MACOP-B chemotherapy regimen (cyclophosphamide, adriamycin, methotrexate, bleomycin, vincristine, prednisone) resulted in complete remission for 15 years.
  • A 76-year-old patient with Gaucher disease suffered from dry-mouth feeling.
  • He developed a left parotid gland tumour.
  • Accumulation of the glucocerebroside in Gaucher disease activates macrophages, inducing release of pro-inflammatory cytokines which may be involved in the pathogenesis of second malignancy.
  • Patients with Gaucher disease bear an increased risk of haematological malignancies; however, aggressive lymphoma has been described only occasionally.
  • The underlying Gaucher disease and sicca syndrome might be implicated as immunological triggers for lymphoma occurrence and its propensity for the parotid gland in these patients.
  • [MeSH-major] Gaucher Disease / complications. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis. Sjogren's Syndrome / complications
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / etiology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / etiology. Male. Neoplasm Staging. Treatment Outcome


89. Foltz LM, Song KW, Connors JM: Hodgkin's lymphoma in adolescents. J Clin Oncol; 2006 Jun 1;24(16):2520-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To compare the clinical presentation, response to treatment, and long-term outcome of Hodgkin's lymphoma (HL) presenting in adolescents and young adults.
  • PATIENTS AND METHODS: The British Columbia Cancer Agency Lymphoid Cancer database was used to identify adolescents (16 years to 21 years) and young adults (22 years to 45 years) receiving primary treatment for HL between 1981 and 2004.
  • There were no significant differences in histologic subtypes, sex, stages, or presence of B symptoms or bulky disease between adolescents and adults.
  • Equal proportions of adolescents and adults were treated with radiation alone (38% v 35%), chemotherapy alone (13% v 15%), or combined-modality programs (49% v 50%).
  • In limited stage disease, 10-year PFS was 89% for adolescents and 89% for adults and OS 96% and 96%, respectively.
  • In advanced stage disease, 10-year PFS was 71% for adolescents and 75% for adults and OS 88% and 86%, respectively.
  • Actuarial risk of second malignancy for adolescents and adults was not different (P = .68).
  • The use of adult treatment protocols is a safe and effective strategy for treating adolescents with HL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / diagnosis. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. British Columbia. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Incidence. Male. Mechlorethamine / administration & dosage. Medical Record Linkage. Neoplasm Staging. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / therapy. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prospective Studies. Radiotherapy, Adjuvant. Registries. Risk Assessment. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735704.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


90. Kobayashi M, Okabayashi T, Okamoto K, Namikawa T, Araki K: Clinicopathological study of cardiac tamponade due to pericardial metastasis originating from gastric cancer. World J Gastroenterol; 2005 Nov 28;11(44):6899-904
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To review the cases reported in the literature, examined their clinicopathological features, and evaluated the efficacy of different therapeutic modalities for this rare condition.
  • No statistical differences in the length of survival time were found between different therapeutic modalities, such as drainage, and local and/or systemic chemotherapy after drainage.
  • However, three cases who underwent systemic chemotherapy survived for more than 10 mo.
  • Cases that developed metachronous cardiac tamponade for more than 2 years after the diagnosis of GC generally survived for a longer period of time, although this was not statistically significant.
  • CONCLUSION: Cases with low levels of CEA, and CEA and/or CA 19-9 should undergo systemic chemotherapy with or without local chemotherapy after drainage.
  • [MeSH-major] Cardiac Tamponade. Heart Neoplasms / complications. Heart Neoplasms / secondary. Pericardium / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. MEDLINE. Male. Middle Aged. Neoplasm Metastasis. Pericarditis / etiology. Pericarditis / pathology. Review Literature as Topic. Survival Rate

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437590.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Number-of-references] 26
  • [Other-IDs] NLM/ PMC4717028
  •  go-up   go-down


91. Stark B, Sharon R, Rechavi G, Attias D, Ballin A, Cividalli G, Burstein Y, Sthoeger D, Abramov A, Zaizov R: Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report. Cancer; 2000 Jan 1;88(1):205-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.
  • BACKGROUND: Preventive cranial radiotherapy (CRT) in childhood acute lymphoblastic leukemia (ALL), although effective, may be associated with neurologic sequelae and second malignancies.
  • Attempts to replace CRT with intensified intrathecal therapy (IT) have shown promise in lower risk subgroups.
  • In the Israel National Study (INS) 89 trial, the efficacy of extended triple IT (TIT) alone for cranial prophylaxis in an enlarged non-high risk group (Non-HRG) was assessed in the context of a modified ALL-Berlin-Frankfurt-Munster (BFM) systemic chemotherapy program.
  • In the INS 89 protocol, all Non-HRG patients were treated with extended TIT x 18 times and systemic therapy based on the BFM 86 protocol, with the addition of etoposide x 4 times.
  • At a median follow-up of 58 months (range, 2-8.5 years), the overall 5-year event free survival (EFS) was 73.5% +/- 3% (standard error ¿SE), and the cumulative central nervous system (CNS) recurrence rate was 4.3% +/- 1.4% (SE) (isolated, 2.3%; combined, 2%).
  • Of the 220 eligible children, 189 (86%) were in the Non-HRG group, and their 5-year EFS was 77.8% +/- 3% (SE).
  • The cumulative CNS recurrence rate for patients without CNS disease at presentation was 3.1% +/- 1% (SE) (isolated, 1.7%; combined, 1.4%).
  • Within the risk subsets defined by the BFM 86 of the Non-HRG, the 5-year EFS rates of the RG (148 patients) and the SRG (41 patients) were 74.8% +/- 4% (SE) and 89.5% +/- 5% (SE), respectively, and the rates of CNS recurrence (isolated and combined) were 4% and 0%, respectively.
  • For the HRG (31 patients), the 5-year EFS and CNS recurrence rates were 47.9% +/- 9% (SE) and 8.
  • 5% +/- 6% (SE), respectively.
  • CONCLUSIONS: Early extended TIT therapy in the context of modified BFM 86 systemic chemotherapy was found to provide adequate CNS protection and systemic leukemia control in patients with non-high risk ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Central Nervous System Neoplasms / secondary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Child. Child, Preschool. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Infant. Injections, Spinal. Israel. Life Tables. Male. Methotrexate / administration & dosage. Radiotherapy, Adjuvant. Risk. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Non Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10618625.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


92. Torre W, Sierra A: Postoperative complications of lung resection after induction chemotherapy using Paclitaxel (and radiotherapy) for advanced non-small lung cancer. J Cardiovasc Surg (Torino); 2002 Aug;43(4):539-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative complications of lung resection after induction chemotherapy using Paclitaxel (and radiotherapy) for advanced non-small lung cancer.
  • BACKGROUND: Locally advanced non-small-cell lung carcinoma is currently treated by multidisciplinary protocols using a combination of chemotherapy, radiotherapy and surgery.
  • However the best strategy for applying these therapeutic measures has not yet been established.
  • One of the difficulties of using these forms of treatment is their toxicity.
  • Our aim was to determine whether the postoperative course of the disease can be influenced by preoperative chemotherapy in any way.
  • METHODS: Nineteen patients were surgically treated after receiving induction treatment between October 1996 and October 1998.
  • The indications for giving induction treatment were: stage III disease in 12 patients (1 Pancoast tumor), lung cancer and solitary brain metastasis in 4 patients, double primary lung cancer in 3 patients (1 synchronous and 2 metachronous).
  • Variables were the chemotherapy treatment time interval from the beginning to surgery, the type of surgery, postoperative mortality and morbidity.
  • Neoadjuvant treatment consisted of chemotherapy in all patients (Paclitaxel, Cysplatin and Vinorelbine in cycles for a mean period of 3 months), and radiotherapy (14 patients).
  • CONCLUSIONS: Surgery for non-small-cell lung carcinoma has to be considered a high-risk procedure.
  • More studies are needed in order to define the exact role of these therapeutic measures.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy. Postoperative Complications / etiology. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Cisplatin / administration & dosage. Female. Humans. Intraoperative Care. Male. Middle Aged. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12124570.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


93. Zhao J, Zhang DC, Wang LJ, Zhang RG: [Diagnosis and treatment of metachronous multiple primary lung cancer]. Ai Zheng; 2002 Jul;21(7):764-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of metachronous multiple primary lung cancer].
  • BACKGROUND & OBJECTIVE: There is much controversy on the diagnosis and treatment of metachronous multiple primary lung cancer (MMPLC).
  • This study was designed to discuss its diagnosis, and to compare the survival rates after different therapeutic modalities.
  • As to the initial cancer and the repeated cancer, they shared the same pathological type in 23 patients, and located on the same side of the lung in 12 patients.
  • The other 20 patients received radiotherapy or/and chemotherapy.
  • CONCLUSIONS: Comprehensive consideration of clinical features may lead to a rational diagnosis and treatment strategy, 5-year survival rate of the operative group, especially the curative group, is significantly higher than that of the non-operative group.
  • The repeated operation, especially the second operation on the same side of the lung, should be performed at the qualified institutes and by the experienced doctors.
  • [MeSH-major] Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479103.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


94. Raderer M, Püspök A, Stummvoll G, Längle F, Chott A: Early cancer of the stomach arising after successful treatment of gastric MALT lymphoma in patients with autoimmune disease. Scand J Gastroenterol; 2003 Mar;38(3):294-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early cancer of the stomach arising after successful treatment of gastric MALT lymphoma in patients with autoimmune disease.
  • BACKGROUND: Extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) arises in lymphoid tissue acquired through chronic antigenic stimulation as exemplified by Helicobacter pylori.
  • The detection of a signet ring cell carcinoma during follow-up endoscopy after successful therapy of MALT lymphoma in a patient with Sjögren's syndrome prompted us to analyse the frequency of subsequent gastric cancer in patients with underlying autoimmune disease (AD).
  • Data analysed included the type of AD, stage of MALT lymphoma, H. pylori status, treatment for MALT lymphoma and response, follow-up, the presence of a secondary cancer, and time to development of cancer.
  • In all patients, histologic samples were reassessed for the extent of gastritis, presence of intestinal metaplasia or focal atrophy at the time of lymphoma diagnosis.
  • RESULTS: A total of eight patients with overt AD at the time of diagnosis of MALT lymphoma were identified.
  • All patients had early stage MALT lymphoma restricted to the mucosa and submucosa at the time of diagnosis, and the presence of H. pylori was found in all cases.
  • Two of these patients achieved complete remission (CR) of the lymphoma following H. pylori eradication, while six were judged unresponsive and underwent chemotherapy, resulting in CR in all cases.
  • One patient died from stroke while being in CR for 2 months following chemotherapy.
  • Two patients (25%) developed early cancer limited to the gastric mucosa while being in CR from lymphoma for 9 and 27 months, respectively, and underwent partial gastrectomy.
  • In the remaining 4 patients, no evidence of lymphoma recurrence or a second malignancy has been found so far by regular follow-up every 3 months for a time-span between 52 and 63 months after initial diagnosis.
  • [MeSH-major] Autoimmune Diseases / therapy. Gastric Mucosa / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Aged. Antineoplastic Combined Chemotherapy Protocols. Austria. Biopsy. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / therapy. Endosonography. Female. Follow-Up Studies. Humans. Metaplasia. Middle Aged. Neoplasm Staging. Polymyalgia Rheumatica / diagnosis. Polymyalgia Rheumatica / therapy. Pyloric Antrum / pathology. Remission Induction. Severity of Illness Index. Sjogren's Syndrome / diagnosis. Sjogren's Syndrome / therapy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12737445.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


95. Maruyama M, Shiono S, Kato H, Sato T, Yanagawa N: [Surgical resection of metachronous multiple lung cancer after complete response of small cell lung cancer; report of a case]. Kyobu Geka; 2006 Feb;59(2):164-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical resection of metachronous multiple lung cancer after complete response of small cell lung cancer; report of a case].
  • A 76-year-old man underwent combination chemotherapy with cisplatin and etoposide and 50 Gy radiotherapy for left-sided small cell lung cancer in 1999.
  • In December 2004, chest computed tomography (CT) revealed a 1 cm nodule in the right lung.
  • Although no diagnosis could be made by bronchoscope, we suspected metachronous multiple lung cancer because of high 18fluorodeoxyglucose uptake with positron emission tomography (PET).
  • [MeSH-major] Adenocarcinoma / surgery. Lung Neoplasms / surgery. Neoplasms, Second Primary / surgery
  • [MeSH-minor] Aged. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Combined Modality Therapy. Humans. Male. Positron-Emission Tomography. Remission Induction. Thoracic Surgery, Video-Assisted. Thoracic Surgical Procedures. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482915.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


96. Kochbati L, Boussen H, Benna F, Belhaj Ali Z, Gammoudi A, Bouaouina N, Besbes M, Ghilen L, Rahal K, Maalej M: [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz]. Cancer Radiother; 2003 Oct;7(5):302-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
  • [Transliterated title] Tumeurs secondaires après traitement pour maladie de Hodgkin en Tunisie. Etude rétrospective à propos de 26 cas observés à l'institut Salah-Azaïz.
  • PURPOSE: To collect second cancers in patients treated for Hodgkin disease (HD) during adolescence and young adulthood at Salah Azaïz Institute of Tunis.
  • METHODS AND PATIENTS: We consider as second cancer all tumours other than HD observed in patients after treatment for HD.
  • RESULTS: Twenty-five patients among 614 treated for HD between 1975 and 1991 developed 26 secondary tumours (4.2%).
  • The first treatment was combined chemotherapy and radiotherapy in 22 cases and only chemotherapy in three cases (stage IV).
  • Mean dose was 41.3 Gy (2 Gy/fraction in 21 and 3.3 in one).
  • Chemotherapy was MOPP (13), MOPP and vinblastine (four), MOPP-ABVD (five), ABVD (two) and vinblastine only in one.
  • Mean delay of second tumours was 114.5 months (40-276).
  • There was five acute myeloid leukaemia, two digestive non-Hodgkin lymphomas, five nodal high-grade lymphomas, three breast cancers (one in man associated with thyroid cancer), five lung cancers (three non-small cell and two of small cell type), two gastric tumours and one rectal cancer, one synovialosarcoma of the knee and one malignant Schwannoma of the neck.
  • CONCLUSION: Second cancer risk after treatment for HD is not low.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14522350.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


97. Brusamolino E, Lunghi F, Orlandi E, Astori C, Passamonti F, Baraté C, Pagnucco G, Baio A, Franchini P, Lazzarino M, Bernasconi C: Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. Haematologica; 2000 Oct;85(10):1032-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.
  • BACKGROUND AND OBJECTIVES: The use of combined modality therapy in early-stage Hodgkin's disease can spare staging laparotomy and reduces the risk of relapse compared to radiation alone.
  • This paper reports on the efficacy and long-term events of a combined modality approach consisting of a brief course of chemotherapy followed by adjuvant radiotherapy, without laparotomy, in early-stage Hodgkin's disease.
  • DESIGN AND METHODS: This study included 78 patients with Hodgkin's disease (20 in stage I and 58 in stage II); 60% had mediastinal enlargement (12% had bulky disease) and 5% had subdiaphragmatic disease.
  • The treatment program consisted of four cycles of ABVD followed by adjuvant radiation to involved sites (43 patients) or involved and contiguous sites of disease (35 patients); radiation doses ranged from 30 to 36 Gy to uninvolved and involved sites, respectively; bulky disease received up to 44 Gy.
  • RESULTS: The treatment program was completed in a median of 6.2 months (range: 5-10).
  • The 5-year relapse-free survival was 97% and overall survival 98%; three patients died, one of disease progression and two of small cell lung carcinoma.
  • Long-term events included three cases of pulmonary fibrosis with symptomatic interstitial disease, one case of dilated cardiomyopathy with cardiac failure (all had received mediastinal radiation) and four cases of dysthyroidism.
  • Second neoplasms included two small cell lung carcinomas and one breast carcinoma.
  • INTERPRETATION AND CONCLUSIONS: In early-stage Hodgkin's disease, four cycles of ABVD followed by adjuvant radiotherapy produced a 5-year overall survival of 98%.
  • Prolonged monitoring for therapy-related long term complications is mandatory in these potentially curable patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Radiotherapy, Adjuvant
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Bleomycin / adverse effects. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Male. Middle Aged. Time Factors. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11025593.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


98. Erkal HS, Serin M, Amdur RJ, Villaret DB, Stringer SP, Mendenhall WM: Squamous cell carcinomas of the soft palate treated with radiation therapy alone or followed by planned neck dissection. Int J Radiat Oncol Biol Phys; 2001 Jun 1;50(2):359-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinomas of the soft palate treated with radiation therapy alone or followed by planned neck dissection.
  • PURPOSE: The present study presents the experience at the University of Florida with treatment of unselected patients with carcinomas of the soft palate with radiation therapy (RT) alone or followed by planned neck dissection.
  • T-stage and overall treatment time significantly affected local control in multivariate analysis.
  • Overall treatment time and planned neck dissection significantly affected nodal control in multivariate analysis.
  • Ultimate local-regional control rates at 5 years were 90% for Stage I, 92% for Stage II, 84% for Stage III, and 60% for Stage IV disease.
  • Overall treatment time and planned neck dissection significantly affected ultimate local-regional control in multivariate analysis.
  • Overall stage, overall treatment time, and planned neck dissection significantly affected overall survival in multivariate analysis.
  • Overall treatment time and planned neck dissection significantly affected cause-specific survival in multivariate analysis.
  • Sixteen patients had synchronous and 14 patients had metachronous carcinomas of the head and neck mucosal sites.
  • Advanced carcinomas of the soft palate may be better treated with RT and concomitant chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Palatal Neoplasms / radiotherapy. Palatal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neck Dissection. Neoplasm Staging. Palate, Soft / pathology. Palate, Soft / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11380222.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R: Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol; 2006 Sep 1;24(25):4202-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
  • METHODS: Four hundred twenty-one patients between 3 years and 21 years of age with nondisseminated medulloblastoma (MB) were prospectively randomly assigned to treatment with 23.4 Gy of CSRT, 55.8 Gy of posterior fossa RT, plus one of two adjuvant chemotherapy regimens: lomustine (CCNU), cisplatin, and vincristine; or cyclophosphamide, cisplatin, and vincristine.
  • EFS was unaffected by sex, race, age, treatment regimen, brainstem involvement, or excessive anaplasia.
  • There were seven second malignancies.
  • CONCLUSION: This study discloses an encouraging EFS rate for children with nondisseminated MB treated with reduced-dose craniospinal radiation and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / radiotherapy. Medulloblastoma / drug therapy. Medulloblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / adverse effects. Child. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Lomustine / administration & dosage. Male. Neoplasm Staging. Neoplasms, Second Primary / diagnosis. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Analysis. Vincristine / administration & dosage


100. Kristinsson SY, Vidarsson B, Agnarsson BA, Haraldsdottir V, Olafsson O, Johannesson GM, Eyjolfsson GI, Bjornsdottir J, Onundarson PT, Reykdal S: Epidemiology of hairy cell leukemia in Iceland. Hematol J; 2002;3(3):145-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is the first study in which all cases diagnosed nationwide over a long period of time in a well defined population are analysed.
  • We report the epidemiology of all HCL patients in Iceland, their clinical characteristics, treatment and follow-up.
  • One patient had a variant of HCL and did not respond to any therapy and one patient died of sepsis before any chemotherapy could be given.
  • Three patients developed a second malignancy (19%).

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12111650.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down






Advertisement